<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278341</url>
  </required_header>
  <id_info>
    <org_study_id>1517-CL-0613</org_study_id>
    <secondary_id>2013-001497-16</secondary_id>
    <nct_id>NCT02278341</nct_id>
  </id_info>
  <brief_title>Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis</brief_title>
  <acronym>Pyrenees</acronym>
  <official_title>A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Patients on Stable Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted to explore a new therapy for anemia in participants with end stage&#xD;
      renal disease (ESRD) on dialysis. Anemia is a reduced number of red blood cells or&#xD;
      hemoglobin. Hemoglobin (which contains iron) is important for the transport of oxygen in your&#xD;
      blood. The purpose of this study was to evaluate if roxadustat is effective and safe in the&#xD;
      maintenance treatment of anemia in ESRD participants on stable dialysis. Roxadustat was&#xD;
      compared to epoetin alfa and darbepoetin alfa, commercially available medicines for treatment&#xD;
      of anemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consisted of three study periods as follows:&#xD;
&#xD;
        -  Screening Period: up to 6 weeks&#xD;
&#xD;
        -  Treatment Period: a minimum of 52 weeks up to a maximum of 104 weeks&#xD;
&#xD;
        -  Follow-up Period: 4 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2014</start_date>
  <completion_date type="Actual">July 6, 2018</completion_date>
  <primary_completion_date type="Actual">June 8, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)]</measure>
    <time_frame>Baseline and weeks 28 to 36</time_frame>
    <description>Baseline Hb was defined as the mean of four central laboratory Hb values; four latest Hb values prior or on the same date as the first study drug intake. For participants who did not have an available Hb value during the week 28-36 period, imputation rules were applied. For analyses without rescue therapy, participants who used rescue therapy after the initiation of rescue therapy were set to missing for 6 weeks from the start date of rescue therapy. If no Hb value was available, an imputation technique was used, with the mean of all available values from Day 1 to minimum (End of Efficacy Emergent Period) carried forward.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From BL to the Average Hb in Weeks 28 to 52 Regardless of Rescue Therapy [US (FDA)]</measure>
    <time_frame>Baseline and weeks 28 to 52</time_frame>
    <description>Baseline Hb was defined as the mean of four central laboratory Hb values: four latest Hb values prior or on the same date as first study drug intake. Change from baseline to the average Hb are observed values. Missing hemoglobin data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model with treatment, baseline hemoglobin, randomization stratification factors and the available non missing hemoglobin for each scheduled week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hb Response During Weeks 28 to 36</measure>
    <time_frame>Weeks 28 to 36</time_frame>
    <description>Hb response during weeks 28-36, was defined as mean Hb from 10-12 g/dL without receiving rescue therapy in the 6 weeks prior to, or during, the evaluation period. The percentages and 95% CI were unadjusted, the exact method of Clopper-Pearson was used for 95% CI. The Efficacy Emergent Period was defined as the evaluation period from the Analysis date of first dose intake up to end of treatment (EOT) Visit or last non-missing Hb assessment (for participants who died during the treatment period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL in Low Density Lipoprotein Cholesterol (LDL-C) to the Average LDL-C of Weeks 12 to 28</measure>
    <time_frame>Baseline and weeks 12 to 28</time_frame>
    <description>Baseline LDL was defined as the LDL value on Day 1. If this value was missing, the latest value prior to first study drug administration was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Monthly Intravenous (IV) Iron Use</measure>
    <time_frame>Day 1 to week 36</time_frame>
    <description>Participants with no or missing medication records of IV Iron have their monthly IV Iron use set to 0 mg. For participants who took IV Iron, but without a dosing frequency, the average values were set to missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL in Short Form-36 (SF-36) Health Survey Physical Functioning (PF) Sub-score to the Average of Weeks 12 to 28</measure>
    <time_frame>Baseline and weeks 12 to 28</time_frame>
    <description>Baseline SF-36 PF was defined as the SF-36 PF value on Day 1.The SF-36 is a Quality of Life (QoL) instrument designed to assess generic health concepts relevant across age, disease, and treatment groups. The SF-36 contains 36 items that measure eight scales: (1) physical functioning (PF); (2) role limitations due to physical health problems (RP); (3) bodily pain (BP); (4) social functioning (SF); (5) general health perceptions (GH); (6) role limitations due to emotional problems (RE); (7) vitality, energy or fatigue (VT); and (8) mental health(MH). Each scale is transformed into 0-100 score, with higher scores indicating better health status. The SF-36 PF consists of 11 questions focused on health and ability to do usual activities, with higher scores indicating better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL in SF-36 Vitality (VT) Sub-score to the Average of Weeks 12 to 28</measure>
    <time_frame>Baseline and weeks 12 to 28</time_frame>
    <description>Baseline VT Subscore was defined as the VT value on Day 1. The SF-36 is a QoL instrument designed to assess generic health concepts relevant across age, disease, and treatment groups. The SF-36 vitality has four questions with score range from 0-100 with higher scores indicating better vitality status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL in Mean Arterial Pressure (MAP) to the Average of Weeks 20 to 28</measure>
    <time_frame>Baseline and weeks 20 to 28</time_frame>
    <description>Baseline MAP was defined as the MAP value on Day 1. If this value was missing, the latest value prior to first study drug administration was used. Mean Arterial Pressure (MAP) is derived as: MAP = (2/3)*DBP + (1/3)*SBP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of an Increase in Blood Pressure</measure>
    <time_frame>Weeks 1 to 36</time_frame>
    <description>Increase in Blood Pressure was defined as either: Systolic Blood Pressure (SBP) ≥ 170 mmHg and an increase from BL ≥ 20 mmHg, or as: Diastolic Blood Pressure (DBP) ≥ 100 mmHg and an increase from BL ≥ 15 mmHg. For participants who have experienced more than one event, only their first event following study treatment was used. Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL in Mean Arterial Pressure (MAP) to the Average MAP Value of Weeks 20 to 28</measure>
    <time_frame>Baseline and weeks 20 to 28</time_frame>
    <description>Baseline MAP was defined as the MAP value on day 1. If this value was missing, the latest value prior to first study drug administration was used. Mean Arterial Pressure (MAP) is derived as: MAP = (2/3)*DBP + (1/3)*SBP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of an Increase in Blood Pressure</measure>
    <time_frame>Weeks 1 to 36</time_frame>
    <description>Increase in Blood Pressure was defined as either: SBP ≥ 170 mmHg and an increase from BL ≥ 20 mmHg, or as: DBP ≥ 100 mmHg and an increase from BL ≥ 15 mmHg. Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Hb Response During Weeks 28 and 36 Regardless of Use of Rescue Therapy</measure>
    <time_frame>Weeks 28 to 36</time_frame>
    <description>Hb response was defined as mean Hb during weeks 28 to 36 within the target range of 10.0 to 12.0 g/dL. The percentages and 95% CI are unadjusted, the exact method of Clopper-Pearson was used for 95% CI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL in Hb to Each Postdosing Time Point</measure>
    <time_frame>Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18,20, 22, 24, 26, 28, 30, 32, 34, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72,76, 80, 84, 88, 92, 96, 100, and 104</time_frame>
    <description>Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb Level Averaged Over Weeks 28 to 36, 44 to 52, and 96 to 104 Without Use of Rescue Therapy</measure>
    <time_frame>Weeks 28 to 36, 44 to 52, and 96 to 104</time_frame>
    <description>Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dose). Averaged Hb values over weeks 28-36, weeks 44-52 and weeks 96-104 are observed values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL in Hb to the Average of Weeks 28 to 36, 44 to 52, and 96 to 104 Regardless of the Use of Rescue Therapy</measure>
    <time_frame>Baseline and weeks 28 to 36, 44 to 52, and 96 to 104</time_frame>
    <description>Change from baseline to the average Hb are observed values. Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Hb Values ≥ 10 g/dL in Weeks 28 to 36, 44 to 52, and 96 to 104 Without Use of Rescue Therapy</measure>
    <time_frame>Weeks 28-36, 44-52 and 96-104</time_frame>
    <description>Percentage for each participant was calculated as Number of Hb values &gt;= 10.0 g/dL / Total number of Hb values*100 in weeks 28 to 36, 44 to 52 and 96 to 104 without use of rescue therapy within 6 weeks prior to and during the 8 week evaluation period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Hb Values Within 10.0 to 12.0 g/dL in Weeks 28 to 36, 44 to 52, and 96 to 104 Without Use of Rescue Therapy</measure>
    <time_frame>Weeks 28-36, 44-52 and 96-104</time_frame>
    <description>Percentage for each participant was calculated as Number of Hb values within 10.0-12.0 g/dL / Total number of Hb values*100 in weeks 28 to 36, 44 to 52 and 96 to 104 without use of rescue therapy within 6 weeks prior to and during the 8 week evaluation period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalizations</measure>
    <time_frame>Baseline to End of Treatment (EOT) (Up to week 104)</time_frame>
    <description>The number of hospitalizations per participant were calculated during the Efficacy Emergent Period. The Efficacy Emergent Period was defined as the evaluation period from the Analysis date of first dose intake up to EOT Visit or last non-missing Hb assessment (for participants who died during the treatment period). It included all Non-Hemodialysis (HD) hospitalizations. The HD days were not counted as hospitalizations, even when performed overnight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Hospitalization Per Year</measure>
    <time_frame>Baseline to EOT (Up to week 104)</time_frame>
    <description>The number of days of hospitalizations per year was calculated as the sum of the durations of all non-HD hospitalizations in days (Date of discharge - Date of admission + 1)] / (duration of efficacy emergent period in days / 365.25). In case of missing dates, the hospitalization duration was imputed by the average duration per stay derived from the participants with non-missing duration within the same treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Hospitalization</measure>
    <time_frame>Baseline to EOT (Up to week 104)</time_frame>
    <description>Time to first hospitalization in years was defined in years as: (First event date during the Efficacy Emergent Period - Analysis date of First dose intake +1)/365.25, and the 'First event date' was defined as 'Date of first Admission and 'Analysis Date of first dose intake. For participants without hospitalization, the time to censoring was calculated as: (Date of End of Efficacy Emergent Period - Analysis Date of first dose intake + 1) / 365.25. Date of End of Efficacy Emergent Period was defined as as the treatment period up to the EOT visit. For participants who have experienced more than one hospitalization, only their first event following study treatment was used. Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Use of Rescue Therapy</measure>
    <time_frame>Baseline to EOT (Up to week 104)</time_frame>
    <description>Rescue therapy was defined as red blood cell (RBC) transfusion for both treatment groups and ESA for roxadustat participants. Only rescue medication that was started during the study treatment and up to end of efficacy emergent period was taken into account and considered as use of rescue medication. For participants who have experienced more than one use of rescue therapy, only their first event following study treatment was used. Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First RBC Transfusion</measure>
    <time_frame>Baseline to EOT (Up to week 104)</time_frame>
    <description>For participants who have experienced more than one RBC transfusion, only their first event following study treatment was used. For RBC transfusions, when the number of units was not given but the volume transfused was, the number of units were estimated by volume transfused/250 mL (for transfusion of packed cell units) or volume transfused/500 mL (for transfusion of full blood). Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Monthly Number of RBC Packs Per Participant</measure>
    <time_frame>Baseline to EOT (Up to week 104)</time_frame>
    <description>During efficacy emergent period, the mean monthly number of RBC packs was calculated as the sum of blood volume and units transfused between the first dose and up to the last dose in the period divided by duration of efficacy emergent period (in days) divided by 28 days. Participants without medication records of RBC have their number of RBC packs and volume set to 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Monthly Volume of RBC Transfusion Per Participant</measure>
    <time_frame>Baseline to EOT (Up to week 104)</time_frame>
    <description>During Efficacy Emergent Period, the mean monthly volume of blood transfused was calculated as the sum of blood volume and units transfused between the first dose and up to the last dose in the period divided by duration of efficacy emergent period (in days) divided by 28 days. The Efficacy Emergent Period was defined as the evaluation period from the Analysis date of first dose intake up to EOT Visit or last non-missing Hb assessment (for participants who died during the treatment period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Use of IV Iron Supplementation</measure>
    <time_frame>Baseline to EOT (Up to week 104)</time_frame>
    <description>For participants who have received more than one IV iron, only their first event following study treatment was used. Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Monthly Intravenous (IV) Iron Per Participant During Weeks 37-52 and Weeks 53-104</measure>
    <time_frame>Weeks 37-52 and weeks 53-104</time_frame>
    <description>Participants with no or missing medication records of IV Iron had their monthly IV Iron use set to 0 mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Oral Iron Use Only</measure>
    <time_frame>Baseline to EOT (Up to week 104)</time_frame>
    <description>Percentage of participants with/without IV iron only was calculated based on total number of participants within the Efficacy Emergent Period. The Efficacy Emergent Period is defined as the evaluation period from the Analysis date of first dose intake up to EOT Visit or last non-missing Hb assessment (for participants who died during the treatment period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL to Each Post-dosing Study Visit in Total Cholesterol</measure>
    <time_frame>Baseline and weeks 8, 28, 52, 104</time_frame>
    <description>Baseline assessment was the assessment from Day 1 visit. If baseline value was missing, then the latest screening period value was used as the baseline regardless of fasting status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL to Each Post-dosing Study Visit in LDL-C/High-density Lipoprotein Cholesterol (HDL-C) Ratio</measure>
    <time_frame>Baseline and weeks 8, 28, 52, 104</time_frame>
    <description>Baseline was defined as the value on Day 1. If baseline value was missing, the latest value prior to first study drug administration was used regardless of fasting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL to Each Postdosing Study Visit in Non-HDL Cholesterol</measure>
    <time_frame>Baseline and weeks 8, 28, 52, 104</time_frame>
    <description>Baseline was defined as the value on Day 1. If baseline value was missing, the latest value prior to first study drug administration was used regardless of fasting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL to Each Postdosing Study Visit in Apolipoproteins A1 (ApoA1)</measure>
    <time_frame>Baseline and weeks 8, 28, 52, 104</time_frame>
    <description>Baseline was defined as the value on Day 1. If baseline value was missing, the latest value prior to first study drug administration was used regardless of fasting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL to Each Postdosing Study Visit in Apolipoproteins B (ApoB)</measure>
    <time_frame>Baseline and weeks 8, 28, 52, 104</time_frame>
    <description>Baseline was defined as the value on Day 1. If baseline value was missing, the latest value prior to first study drug administration was used regardless of fasting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL to Each Postdosing Study Visit in ApoB/ApoA1 Ratio</measure>
    <time_frame>Baseline and weeks 8, 28, 52, 104</time_frame>
    <description>Baseline was defined as the value on Day 1. If baseline value was missing, the latest value prior to first study drug administration was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mean LDL Cholesterol &lt; 100 mg/dL Over Weeks 12 to 28</measure>
    <time_frame>Weeks 12 to 28</time_frame>
    <description>Missing category for Fasting Only includes non-fasting participants and the participants with missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With CKD Who Achieved Antihypertensive Treatment Goal</measure>
    <time_frame>Weeks 12 to 28</time_frame>
    <description>Achieved antihypertensive treatment goal was defined as SBP &lt; 140 mmHg and DBP &lt; 90 mmHg over an evaluation period based on the average of available values in weeks 12-28 (pre-dialysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL to the Average of Weeks 12 to 28 in SF-36 Physical Component Score (PCS)</measure>
    <time_frame>Baseline and weeks 12 to 28</time_frame>
    <description>Baseline SF-36 PCS was defined as the SF-36 PCS value on Day 1. SF-36 contains 36-item that measures 8 scales with scores ranging from 0-100: physical functioning (PF); role limitations due to physical health problems (RP); bodily pain (BP); social functioning (SF); general health perceptions (GH); role limitations due to emotional problems (RE); vitality, energy or fatigue (VT); and mental health (MH). These scores are normed to the US population (norm-based scoring had very little impact on results when data was collected in Western European countries) to have a mean of 50 and standard deviation of 10. The PCS was calculated based on all 8 scales and ranges from 5.02-79.78. For each of these above scales, higher scores always indicating better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL to the Average of Weeks 12 to 28 in Anemia Subscale (AnS) (&quot;Additional Concerns&quot;) of Functional Assessment of Cancer Therapy-Anemia (FACT-An) Score</measure>
    <time_frame>Baseline and weeks 12 to 28</time_frame>
    <description>Baseline FACT-An AnS was defined as the FACT-An AnS value on Day 1. Together with the Functional Assessment of Cancer Therapy - General (FACT-G), the Anemia Subscale (AnS) is referred to as the FACT-An Total. The AnS scale contains 13 fatigue specific items (the Fatigue Score) plus 7 items related to anemia. The Anemia AnS score range is 0 to 80. For the above score, a higher score indicates better QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL to the Average Value of Weeks 12 to 28 in Total FACT-An Score</measure>
    <time_frame>Baseline and weeks 12 to 28</time_frame>
    <description>Baseline FACT-An Total Score was defined on Day 1. Total Fact-An score is composed of FACT-G and Ans scales. FACT-G contains 27 items that cover four dimensions of well-being: physical (PWB) - 7 items, functional (FWB) - 7 items, social/family (SWB) - 7 items, and emotional (EWB) - 6 items. The AnS scale contains 13 fatigue specific items (the Fatigue Score) plus 7 items related to anemia. The total score is obtained by summation of the scores from PWB, SWB, EWB, FWB and AnS. The FACT-An Total Score scale range is 0-188. A higher score indicates better QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL to the Average of Weeks 12 to 28 in Euroqol Questionnaire-5 Dimensions 5 Levels (EQ-5D 5L) Visual Analogue Scale (VAS) Score</measure>
    <time_frame>Baseline and weeks 12 to 28</time_frame>
    <description>Baseline assessment was defined as the value on Day 1. The EuroQol Questionnaire -5 Dimensions -5 Levels (EQ-5D-5L) is a self-reported questionnaire, used as a measure of respondents' Health Related Quality of Life (HRQoL) and utility values. The EQ-5D consists of the descriptive system and the visual analogue scale (VAS). The EQ-5D descriptive system comprises 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, extreme problems. The VAS records the respondent's self rated health status on a graduated (0-100) scale, where the endpoints are labeled 'Best imaginable health state' and 'Worst imaginable health state' with higher scores for higher HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvements Measured by Patients' Global Impression of Change (PGIC)</measure>
    <time_frame>Baseline and weeks 8, 12, 28, 36, 52, 76, 104</time_frame>
    <description>The PGIC is a patient-rated instrument that measures change in participant's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), when compared to the start of treatment. The percentage of participants presented includes very much improved, much improved and minimally improved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL in Serum Hepcidin</measure>
    <time_frame>Baseline and weeks 4, 12, 20, 36, 52, 104, and End of Study (EOS - up to 108 weeks)</time_frame>
    <description>Baseline assessment was assessment from Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL in Serum Ferritin</measure>
    <time_frame>Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 104, and EOS (up to 108 weeks)</time_frame>
    <description>Baseline assessment was assessment from Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL in Transferrin Saturation (TSAT)</measure>
    <time_frame>Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 104 and EOS (up to 108 weeks)</time_frame>
    <description>Baseline assessment was assessment from Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL in Glycated Hemoglobin (HbA1c) Level to Weeks 12, 28, 36, 44, 52, 60, 84, 104 and EOS (up to Week 108)</measure>
    <time_frame>Baseline and weeks 12, 28, 36, 44, 52, 60, 84, 104 and EOS (up to 108 weeks)</time_frame>
    <description>Percentage of change from baseline to each study visit were calculated for HbA1c. Baseline assessment was assessment from Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to EOS (Up to week 108)</time_frame>
    <description>Safety was assessed by evaluation of the following variables: (TEAEs; frequency, severity, seriousness, and relationship to study drug), Vital signs (systolic and diastolic blood pressure, pulse, respiratory rate and weight), Clinical laboratory variables (hematology, biochemistry including liver enzymes and total bilirubin, and urinalysis), Physical examination, 12-lead electrocardiogram (ECG) and Vascular Access Thrombosis. All AEs collected during the Safety Emergent Period were counted as TEAE. The TEAE was defined as an adverse event (AE) if it was observed after starting administration of the roxadustat or ESA. Any clinically significant abnormalities were reported as an AEs. All reported deaths after the first study drug administration and up to 28 days after the Analysis Date of Last Dose and considering last dosing frequency.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">838</enrollment>
  <condition>Anemia</condition>
  <condition>End Stage Renal Disease (ESRD)</condition>
  <arm_group>
    <arm_group_label>Roxadustat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESA (Erythropoiesis Stimulating Agent) treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from the epoetin alfa to darbepoetin alfa or vice versa.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roxadustat</intervention_name>
    <description>Participants received initial dose of roxadustat orally as a tablet in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
    <arm_group_label>Roxadustat</arm_group_label>
    <other_name>ASP1517</other_name>
    <other_name>FG-4592</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alfa</intervention_name>
    <description>Participants received epoetin alfa via intravenous or subcutaneous injection, once a week, twice a week, or three times a week (TIW). Epoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of epoetin alfa was per UK SmPC of Eprex®. Participants received IV iron supplementation according to the standard of care.</description>
    <arm_group_label>ESA (Erythropoiesis Stimulating Agent) treatment</arm_group_label>
    <other_name>Eprex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <description>Participants received darbepoetin alfa via intravenous or subcutaneous injection, once a week or once every other week. Darbepoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of darbepoetin alfa was per EU SmPC of Aranesp®. Participants received IV iron supplementation according to the standard of care.</description>
    <arm_group_label>ESA (Erythropoiesis Stimulating Agent) treatment</arm_group_label>
    <other_name>Aranesp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron</intervention_name>
    <description>Oral iron treatment was recommended for supplementation to support erythropoiesis and as first-line treatment for iron deficiency, unless participant was intolerant to this treatment. For participants receiving roxadustat the recommended daily dose was 200 mg of elemental iron. Participants were advised to take roxadustat at least 1 hour before or 1 hour after oral iron. Intravenous iron supplementation for participants receiving roxadustat was allowed if all of the following criteria were met: The participant's Hb level had not responded adequately to roxadustat following two consecutive dose increases or reached the maximum dose limit, and participant's ferritin was &lt; 100 ng/mL (&lt; 220 pmol/L) or TSAT &lt; 20%, or the participant was intolerant of oral iron therapy. For participants treated with epoetin alfa or darbepoetin alfa, IV iron supplementation was given according to standard of care.</description>
    <arm_group_label>ESA (Erythropoiesis Stimulating Agent) treatment</arm_group_label>
    <arm_group_label>Roxadustat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Main Inclusion:&#xD;
&#xD;
          -  Participant is on stable hemodialysis (HD), hemodiafiltration (HDF) or peritoneal&#xD;
             dialysis (PD) treatment with the same mode of dialysis for ≥4 months prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Participant is on IV or SC epoetin or IV or SC darbepoetin alfa treatment for ≥8 weeks&#xD;
             prior to randomization with stable weekly doses (during 4 weeks prior to&#xD;
             randomization).&#xD;
&#xD;
          -  Mean of the participant's three most recent Hb values, as measured by central&#xD;
             laboratory, during the Screening Period.&#xD;
&#xD;
          -  Participant's alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are&#xD;
             ≤3 x upper limit of normal (ULN), and total bilirubin (TBL) is ≤1.5 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Main Exclusion:&#xD;
&#xD;
          -  Participant has received a red blood cell (RBC) transfusion within 8 weeks prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Participant has a known hereditary hematologic disease such as thalassemia or sickle&#xD;
             cell anemia, pure red cell aplasia, or other known causes for anemia other than&#xD;
             Chronic Kidney Disease (CKD).&#xD;
&#xD;
          -  Participant has had a myocardial infarction, acute coronary syndrome, stroke, seizure,&#xD;
             or a thrombotic/thrombo-embolic event (e.g., deep vein thrombosis or pulmonary&#xD;
             embolism) within 12 weeks prior to randomization.&#xD;
&#xD;
          -  Participant has had uncontrolled hypertension, in the opinion of the investigator,&#xD;
             within 2 weeks prior to randomization.&#xD;
&#xD;
          -  Participant has a history of malignancy, except for the following: cancers determined&#xD;
             to be cured or in remission for ≥5 years, curatively resected basal cell or squamous&#xD;
             cell skin cancers, cervical cancer in situ, or resected colonic polyps.&#xD;
&#xD;
          -  Participant has had any prior organ transplant (that has not been explanted), or&#xD;
             participant is scheduled for organ transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Physician</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site BE32004</name>
      <address>
        <city>Brussels</city>
        <state>Flemish Brabant</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32001</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32019</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32002</name>
      <address>
        <city>Antwerp</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32012</name>
      <address>
        <city>Baudour</city>
        <zip>7331</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32017</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32003</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32013</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32011</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35925</name>
      <address>
        <city>Blagoevgrad</city>
        <zip>2700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35931</name>
      <address>
        <city>Haskovo</city>
        <zip>6300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35915</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35909</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35919</name>
      <address>
        <city>Plovdiv</city>
        <zip>4003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35920</name>
      <address>
        <city>Rousse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35938</name>
      <address>
        <city>Shumen</city>
        <zip>9700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35924</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35906</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35921</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35907</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35916</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35918</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35903</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35937</name>
      <address>
        <city>Yambol</city>
        <zip>8600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HR38509</name>
      <address>
        <city>Zagreb</city>
        <state>Grad Zagreb</state>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HR38508</name>
      <address>
        <city>Cakovec</city>
        <zip>40000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HR38505</name>
      <address>
        <city>Karlovac</city>
        <zip>47000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HR38507</name>
      <address>
        <city>Osijek</city>
        <zip>31 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HR38506</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HR38504</name>
      <address>
        <city>Slavonski Brod</city>
        <zip>35000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HR38501</name>
      <address>
        <city>Zadar</city>
        <zip>23 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42008</name>
      <address>
        <city>Liberec</city>
        <zip>46063</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42021</name>
      <address>
        <city>Praha 6</city>
        <zip>169 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42015</name>
      <address>
        <city>Rakovnik</city>
        <zip>26929</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33005</name>
      <address>
        <city>Amiens cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33010</name>
      <address>
        <city>La Tronche</city>
        <zip>38701</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33055</name>
      <address>
        <city>Saint Ouen</city>
        <zip>93400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33007</name>
      <address>
        <city>Saint Priez En Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33056</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GE99503</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GE99504</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GE99508</name>
      <address>
        <city>Tbilisi</city>
        <zip>159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49056</name>
      <address>
        <city>Dormagen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41540</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49067</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49073</name>
      <address>
        <city>Cloppenburg</city>
        <zip>49661</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49008</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49054</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40210</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49020</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49065</name>
      <address>
        <city>Hamburg</city>
        <zip>23397</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49075</name>
      <address>
        <city>Heilbronn</city>
        <zip>74076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49001</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49070</name>
      <address>
        <city>Muenchen</city>
        <zip>81695</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49002</name>
      <address>
        <city>Solingen</city>
        <zip>42653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49071</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36033</name>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36036</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36031</name>
      <address>
        <city>Gyor</city>
        <zip>9002</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36026</name>
      <address>
        <city>Kaposvar</city>
        <zip>H 7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36027</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36032</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36035</name>
      <address>
        <city>Pecs</city>
        <zip>7633</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36034</name>
      <address>
        <city>Salgotarjan</city>
        <zip>3100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36004</name>
      <address>
        <city>Szeged</city>
        <zip>6724</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36046</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36006</name>
      <address>
        <city>Szombathely</city>
        <zip>H 9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36003</name>
      <address>
        <city>Zalsaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39028</name>
      <address>
        <city>Prato</city>
        <state>Frazione Di Galciana</state>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39039</name>
      <address>
        <city>Cremona</city>
        <state>Lombardia</state>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39014</name>
      <address>
        <city>Mestre</city>
        <state>Venezia</state>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39010</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39008</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39006</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39037</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39022</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39036</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39005</name>
      <address>
        <city>Roma</city>
        <zip>122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39035</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39032</name>
      <address>
        <city>Trieste</city>
        <zip>34142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48002</name>
      <address>
        <city>Katowice</city>
        <zip>40 027</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48001</name>
      <address>
        <city>Krakow</city>
        <zip>30 501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48013</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48005</name>
      <address>
        <city>Warszawa</city>
        <zip>00 507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48006</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48009</name>
      <address>
        <city>Wroclaw</city>
        <zip>51 124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48014</name>
      <address>
        <city>Zamosc</city>
        <zip>20-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PT35121</name>
      <address>
        <city>Almada</city>
        <zip>2800-455</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PT35127</name>
      <address>
        <city>Aveiro</city>
        <zip>3800-266</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PT35139</name>
      <address>
        <city>Cascais</city>
        <zip>2750-663</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PT35117</name>
      <address>
        <city>Faro</city>
        <zip>8005-546</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PT35128</name>
      <address>
        <city>Gaeiras</city>
        <zip>2510-702</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PT35114</name>
      <address>
        <city>Leiria</city>
        <zip>2400-441</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PT35102</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PT35122</name>
      <address>
        <city>Setubal</city>
        <zip>2900-655</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40018</name>
      <address>
        <city>Bucharest</city>
        <zip>011794</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40015</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40019</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40003</name>
      <address>
        <city>Bucuresti</city>
        <zip>22328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40004</name>
      <address>
        <city>Oradea</city>
        <zip>410562</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70008</name>
      <address>
        <city>Kaluga</city>
        <zip>248007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70051</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70005</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70003</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603032</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70004</name>
      <address>
        <city>Omsk</city>
        <zip>644112</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70014</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70072</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70002</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70011</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70050</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197374</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70030</name>
      <address>
        <city>Sankt-Peterburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70006</name>
      <address>
        <city>Smolensk</city>
        <zip>214006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70037</name>
      <address>
        <city>Volgograd</city>
        <zip>404120</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70001</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RS38102</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RS38105</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RS38120</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RS38104</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RS38117</name>
      <address>
        <city>Krusevac</city>
        <zip>37000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RS38101</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RS38116</name>
      <address>
        <city>Zrenjanin</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42102</name>
      <address>
        <city>Koshice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42119</name>
      <address>
        <city>Levice</city>
        <zip>93401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42120</name>
      <address>
        <city>Lučenec</city>
        <zip>984 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42113</name>
      <address>
        <city>Puchov</city>
        <zip>020 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42116</name>
      <address>
        <city>Senica</city>
        <zip>90501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34041</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34009</name>
      <address>
        <city>El Ejido</city>
        <state>Almeria</state>
        <zip>04700</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34010</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34030</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34011</name>
      <address>
        <city>Galdakao</city>
        <state>Vizcaya</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34002</name>
      <address>
        <city>Badalona-Barcelona</city>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34008</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34006</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34017</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34037</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34052</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44087</name>
      <address>
        <city>Brighton</city>
        <state>EastSussex</state>
        <zip>BN2 5BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44011</name>
      <address>
        <city>Canterbury</city>
        <state>Kent</state>
        <zip>CT1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44080</name>
      <address>
        <city>Stoke on Trent</city>
        <state>Staffordshire</state>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44008</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44010</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44081</name>
      <address>
        <city>Leicester</city>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44079</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44001</name>
      <address>
        <city>Swansea</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/study.aspx?ID=364</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 28, 2014</study_first_submitted>
  <study_first_submitted_qc>October 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2014</study_first_posted>
  <results_first_submitted>May 26, 2020</results_first_submitted>
  <results_first_submitted_qc>August 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 26, 2020</results_first_posted>
  <disposition_first_submitted>May 30, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>May 30, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 31, 2018</disposition_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP1517</keyword>
  <keyword>FG-4592</keyword>
  <keyword>Anemia</keyword>
  <keyword>End Stage Renal Disease (ESRD)</keyword>
  <keyword>Erythropoetin Stimulating Agents (ESAs)</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Hematopoetic Agents</keyword>
  <keyword>HIF-PH inhibitor</keyword>
  <keyword>Hemoglobin</keyword>
  <keyword>Dialysis</keyword>
  <keyword>roxadustat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
    <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02278341/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02278341/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study population consisted of participants with end-stage renal disease (ESRD) who were on stable hemodialysis (HD) or peritoneal dialysis (PD), and were also on stable treatment with epoetin (i.e. epoetin alfa, beta, theta, zeta, delta or omega) or darbepoetin alfa for anemia.</recruitment_details>
      <pre_assignment_details>Participants were randomized in a 1:1 ratio to roxadustat or ESA (epoetin alfa or darbepoetin alfa). Randomization was stratified by 5 factors: previous ESA treatment, region, history of cardiovascular, cerebrovascular or thromboembolic diseases, average weekly ESA dose 4 weeks prior to randomization and the screening hemaglobin (Hb) value.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Roxadustat</title>
          <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
        </group>
        <group group_id="P2">
          <title>ESA (Erythropoiesis-Stimulating Agent)</title>
          <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="415"/>
                <participants group_id="P2" count="421"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="414"/>
                <participants group_id="P2" count="420"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="297"/>
                <participants group_id="P2" count="329"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but never received study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis population was the All Randomized, which consisted of participants who were randomized into the study and had the available data.</population>
      <group_list>
        <group group_id="B1">
          <title>Roxadustat</title>
          <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
        </group>
        <group group_id="B2">
          <title>ESA (Erythropoiesis-Stimulating Agent)</title>
          <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="415"/>
            <count group_id="B2" value="421"/>
            <count group_id="B3" value="836"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>The analysis population was the All Randomized population.</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="13.8"/>
                    <measurement group_id="B2" value="61.8" spread="13.4"/>
                    <measurement group_id="B3" value="61.4" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>The analysis population was the All Randomized population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="354"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="246"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>The analysis population was the All Randomized population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>WHITE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="405"/>
                    <measurement group_id="B2" value="408"/>
                    <measurement group_id="B3" value="813"/>
                  </measurement_list>
                </category>
                <category>
                  <title>BLACK OR AFRICAN AMERICAN</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ASIAN</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OTHER</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Hemoglobin (Hb) Value</title>
          <population>The analysis population was the All Randomized population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=11.0 g/dL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                    <measurement group_id="B2" value="266"/>
                    <measurement group_id="B3" value="533"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;11.0 g/dL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Mean Hb</title>
          <description>Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dose).</description>
          <population>The analysis population was the All Randomized population.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.75" spread="0.62"/>
                    <measurement group_id="B2" value="10.77" spread="0.62"/>
                    <measurement group_id="B3" value="10.76" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)]</title>
        <description>Baseline Hb was defined as the mean of four central laboratory Hb values; four latest Hb values prior or on the same date as the first study drug intake. For participants who did not have an available Hb value during the week 28-36 period, imputation rules were applied. For analyses without rescue therapy, participants who used rescue therapy after the initiation of rescue therapy were set to missing for 6 weeks from the start date of rescue therapy. If no Hb value was available, an imputation technique was used, with the mean of all available values from Day 1 to minimum (End of Efficacy Emergent Period) carried forward.</description>
        <time_frame>Baseline and weeks 28 to 36</time_frame>
        <population>The analysis population was the Per Protocol Set (PPS) which consisted of all Full Analysis Set (FAS) participants who did not meet any of exclusion criteria from the PPS. The FAS consisted of all randomized participants who received at least one dose of study drug and had at least one post-dose valid Hb assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)]</title>
          <description>Baseline Hb was defined as the mean of four central laboratory Hb values; four latest Hb values prior or on the same date as the first study drug intake. For participants who did not have an available Hb value during the week 28-36 period, imputation rules were applied. For analyses without rescue therapy, participants who used rescue therapy after the initiation of rescue therapy were set to missing for 6 weeks from the start date of rescue therapy. If no Hb value was available, an imputation technique was used, with the mean of all available values from Day 1 to minimum (End of Efficacy Emergent Period) carried forward.</description>
          <population>The analysis population was the Per Protocol Set (PPS) which consisted of all Full Analysis Set (FAS) participants who did not meet any of exclusion criteria from the PPS. The FAS consisted of all randomized participants who received at least one dose of study drug and had at least one post-dose valid Hb assessment.</population>
          <units>g/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="354"/>
                <count group_id="O2" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.428" lower_limit="0.350" upper_limit="0.506"/>
                    <measurement group_id="O2" value="0.193" lower_limit="0.117" upper_limit="0.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The model includes treatment arm, region, CV History, previous ESA treatment, visits and visit by treatment as categorical variables and baseline Hb and baseline Hb by visit as continuous variable.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non Inferiority, Margin = -0.75</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for non-inferiority test based on 1-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.235</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.132</ci_lower_limit>
            <ci_upper_limit>0.339</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From BL to the Average Hb in Weeks 28 to 52 Regardless of Rescue Therapy [US (FDA)]</title>
        <description>Baseline Hb was defined as the mean of four central laboratory Hb values: four latest Hb values prior or on the same date as first study drug intake. Change from baseline to the average Hb are observed values. Missing hemoglobin data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model with treatment, baseline hemoglobin, randomization stratification factors and the available non missing hemoglobin for each scheduled week.</description>
        <time_frame>Baseline and weeks 28 to 52</time_frame>
        <population>The analysis population was the All Randomized, which consisted of participants who received at least one dose of study drug, and who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL to the Average Hb in Weeks 28 to 52 Regardless of Rescue Therapy [US (FDA)]</title>
          <description>Baseline Hb was defined as the mean of four central laboratory Hb values: four latest Hb values prior or on the same date as first study drug intake. Change from baseline to the average Hb are observed values. Missing hemoglobin data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model with treatment, baseline hemoglobin, randomization stratification factors and the available non missing hemoglobin for each scheduled week.</description>
          <population>The analysis population was the All Randomized, which consisted of participants who received at least one dose of study drug, and who had available data.</population>
          <units>g/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.363" lower_limit="0.288" upper_limit="0.438"/>
                    <measurement group_id="O2" value="0.192" lower_limit="0.121" upper_limit="0.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The model includes treatment arm, region, CV History, previous ESA treatment as categorical variables and baseline Hb as continuous variable. Statistical analysis used was ANCOVA model with multiple imputations (MI). Missing hemoglobin data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-Inferiority, Margin = -0.75</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for non-inferiority test based on 1-sided significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.171</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.082</ci_lower_limit>
            <ci_upper_limit>0.261</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hb Response During Weeks 28 to 36</title>
        <description>Hb response during weeks 28-36, was defined as mean Hb from 10-12 g/dL without receiving rescue therapy in the 6 weeks prior to, or during, the evaluation period. The percentages and 95% CI were unadjusted, the exact method of Clopper-Pearson was used for 95% CI. The Efficacy Emergent Period was defined as the evaluation period from the Analysis date of first dose intake up to end of treatment (EOT) Visit or last non-missing Hb assessment (for participants who died during the treatment period).</description>
        <time_frame>Weeks 28 to 36</time_frame>
        <population>The analysis population was the PPS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Response During Weeks 28 to 36</title>
          <description>Hb response during weeks 28-36, was defined as mean Hb from 10-12 g/dL without receiving rescue therapy in the 6 weeks prior to, or during, the evaluation period. The percentages and 95% CI were unadjusted, the exact method of Clopper-Pearson was used for 95% CI. The Efficacy Emergent Period was defined as the evaluation period from the Analysis date of first dose intake up to end of treatment (EOT) Visit or last non-missing Hb assessment (for participants who died during the treatment period).</description>
          <population>The analysis population was the PPS.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
                <count group_id="O2" value="397"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" lower_limit="80.2" upper_limit="87.7"/>
                    <measurement group_id="O2" value="82.4" lower_limit="78.3" upper_limit="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A generalized linear model was used to estimate the difference in response rates between the arms, as an approximation for the Miettinen and Nurminen method, adjusting for following covariates: region, previous ESA treatment, cardiovascular history and baseline Hb as categorical variables.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of roxadustat versus ESA (the non-inferiority margin for the difference between groups is -15%).</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>p-value for non-inferiority test based on 1-sided significance level.</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference of Percentages</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>7.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL in Low Density Lipoprotein Cholesterol (LDL-C) to the Average LDL-C of Weeks 12 to 28</title>
        <description>Baseline LDL was defined as the LDL value on Day 1. If this value was missing, the latest value prior to first study drug administration was used.</description>
        <time_frame>Baseline and weeks 12 to 28</time_frame>
        <population>The analysis population was the FAS, with participants who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL in Low Density Lipoprotein Cholesterol (LDL-C) to the Average LDL-C of Weeks 12 to 28</title>
          <description>Baseline LDL was defined as the LDL value on Day 1. If this value was missing, the latest value prior to first study drug administration was used.</description>
          <population>The analysis population was the FAS, with participants who had available data.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.459" lower_limit="-0.517" upper_limit="-0.401"/>
                    <measurement group_id="O2" value="-0.082" lower_limit="-0.138" upper_limit="-0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The model includes treatment arm, region, CV History, previous ESA treatment, visits and visit by treatment as categorical variables and baseline LDL, baseline Hb as continuous variables.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>-0.377</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.451</ci_lower_limit>
            <ci_upper_limit>-0.304</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Monthly Intravenous (IV) Iron Use</title>
        <description>Participants with no or missing medication records of IV Iron have their monthly IV Iron use set to 0 mg. For participants who took IV Iron, but without a dosing frequency, the average values were set to missing.</description>
        <time_frame>Day 1 to week 36</time_frame>
        <population>The analysis population was the FAS, with participants who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Monthly Intravenous (IV) Iron Use</title>
          <description>Participants with no or missing medication records of IV Iron have their monthly IV Iron use set to 0 mg. For participants who took IV Iron, but without a dosing frequency, the average values were set to missing.</description>
          <population>The analysis population was the FAS, with participants who had available data.</population>
          <units>mg per month</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" lower_limit="14.0" upper_limit="29.3"/>
                    <measurement group_id="O2" value="53.5" lower_limit="46.0" upper_limit="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The model includes treatment arm, region, CV History, previous ESA treatment as categorical variables and baseline Hb as continuous variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LSM Difference</param_type>
            <param_value>-31.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.4</ci_lower_limit>
            <ci_upper_limit>-22.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL in Short Form-36 (SF-36) Health Survey Physical Functioning (PF) Sub-score to the Average of Weeks 12 to 28</title>
        <description>Baseline SF-36 PF was defined as the SF-36 PF value on Day 1.The SF-36 is a Quality of Life (QoL) instrument designed to assess generic health concepts relevant across age, disease, and treatment groups. The SF-36 contains 36 items that measure eight scales: (1) physical functioning (PF); (2) role limitations due to physical health problems (RP); (3) bodily pain (BP); (4) social functioning (SF); (5) general health perceptions (GH); (6) role limitations due to emotional problems (RE); (7) vitality, energy or fatigue (VT); and (8) mental health(MH). Each scale is transformed into 0-100 score, with higher scores indicating better health status. The SF-36 PF consists of 11 questions focused on health and ability to do usual activities, with higher scores indicating better health status.</description>
        <time_frame>Baseline and weeks 12 to 28</time_frame>
        <population>The analysis population was the PPS, with participants who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL in Short Form-36 (SF-36) Health Survey Physical Functioning (PF) Sub-score to the Average of Weeks 12 to 28</title>
          <description>Baseline SF-36 PF was defined as the SF-36 PF value on Day 1.The SF-36 is a Quality of Life (QoL) instrument designed to assess generic health concepts relevant across age, disease, and treatment groups. The SF-36 contains 36 items that measure eight scales: (1) physical functioning (PF); (2) role limitations due to physical health problems (RP); (3) bodily pain (BP); (4) social functioning (SF); (5) general health perceptions (GH); (6) role limitations due to emotional problems (RE); (7) vitality, energy or fatigue (VT); and (8) mental health(MH). Each scale is transformed into 0-100 score, with higher scores indicating better health status. The SF-36 PF consists of 11 questions focused on health and ability to do usual activities, with higher scores indicating better health status.</description>
          <population>The analysis population was the PPS, with participants who had available data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.050" lower_limit="-0.640" upper_limit="0.740"/>
                    <measurement group_id="O2" value="-0.155" lower_limit="-0.825" upper_limit="0.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The model includes treatment arm, region, CV History, previous ESA treatment, visits (week 8, week 12, week 28) and visit by treatment as categorical variables, and baseline SF-36 PF, baseline Hb as continuous variables.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The margin for non-inferiority was -3.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>p-value for non-inferiority test based on 1-sided significance level</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.205</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.649</ci_lower_limit>
            <ci_upper_limit>1.059</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL in SF-36 Vitality (VT) Sub-score to the Average of Weeks 12 to 28</title>
        <description>Baseline VT Subscore was defined as the VT value on Day 1. The SF-36 is a QoL instrument designed to assess generic health concepts relevant across age, disease, and treatment groups. The SF-36 vitality has four questions with score range from 0-100 with higher scores indicating better vitality status.</description>
        <time_frame>Baseline and weeks 12 to 28</time_frame>
        <population>The analysis population was the PPS, with participants who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL in SF-36 Vitality (VT) Sub-score to the Average of Weeks 12 to 28</title>
          <description>Baseline VT Subscore was defined as the VT value on Day 1. The SF-36 is a QoL instrument designed to assess generic health concepts relevant across age, disease, and treatment groups. The SF-36 vitality has four questions with score range from 0-100 with higher scores indicating better vitality status.</description>
          <population>The analysis population was the PPS, with participants who had available data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.460" lower_limit="-0.329" upper_limit="1.249"/>
                    <measurement group_id="O2" value="-0.396" lower_limit="-1.165" upper_limit="0.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The model includes treatment arm, region, CV History, previous ESA treatment, visits (week 8, week 12, week 28) and visit by treatment as categorical variables, and baseline SF-36 VT, baseline Hb as continuous variables.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The margin for non-inferiority was -3.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.856</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.115</ci_lower_limit>
            <ci_upper_limit>1.828</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL in Mean Arterial Pressure (MAP) to the Average of Weeks 20 to 28</title>
        <description>Baseline MAP was defined as the MAP value on Day 1. If this value was missing, the latest value prior to first study drug administration was used. Mean Arterial Pressure (MAP) is derived as: MAP = (2/3)*DBP + (1/3)*SBP.</description>
        <time_frame>Baseline and weeks 20 to 28</time_frame>
        <population>The analysis population was the PPS, with participants who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL in Mean Arterial Pressure (MAP) to the Average of Weeks 20 to 28</title>
          <description>Baseline MAP was defined as the MAP value on Day 1. If this value was missing, the latest value prior to first study drug administration was used. Mean Arterial Pressure (MAP) is derived as: MAP = (2/3)*DBP + (1/3)*SBP.</description>
          <population>The analysis population was the PPS, with participants who had available data.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.969" lower_limit="-1.838" upper_limit="-0.099"/>
                    <measurement group_id="O2" value="-0.120" lower_limit="-0.972" upper_limit="0.732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The model includes treatment arm, region, CV History, previous ESA treatment, visits and visit by treatment as categorical variables, and baseline MAP, baseline Hb as continuous variables.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The margin for non-inferiority was 1.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>p-value for non-inferiority test based on 1-sided significance level</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>-0.849</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.971</ci_lower_limit>
            <ci_upper_limit>0.273</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Occurrence of an Increase in Blood Pressure</title>
        <description>Increase in Blood Pressure was defined as either: Systolic Blood Pressure (SBP) ≥ 170 mmHg and an increase from BL ≥ 20 mmHg, or as: Diastolic Blood Pressure (DBP) ≥ 100 mmHg and an increase from BL ≥ 15 mmHg. For participants who have experienced more than one event, only their first event following study treatment was used. Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
        <time_frame>Weeks 1 to 36</time_frame>
        <population>The analysis population was the PPS, with participants who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met. .</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Occurrence of an Increase in Blood Pressure</title>
          <description>Increase in Blood Pressure was defined as either: Systolic Blood Pressure (SBP) ≥ 170 mmHg and an increase from BL ≥ 20 mmHg, or as: Diastolic Blood Pressure (DBP) ≥ 100 mmHg and an increase from BL ≥ 15 mmHg. For participants who have experienced more than one event, only their first event following study treatment was used. Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
          <population>The analysis population was the PPS, with participants who had available data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
                <count group_id="O2" value="397"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" lower_limit="8.5" upper_limit="14.9"/>
                    <measurement group_id="O2" value="11.1" lower_limit="8.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" lower_limit="12.2" upper_limit="19.6"/>
                    <measurement group_id="O2" value="15.4" lower_limit="11.9" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" lower_limit="14.0" upper_limit="28.2"/>
                    <measurement group_id="O2" value="23.5" lower_limit="16." upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio was calculated using stratified Cox Proportional Hazards regression stratifying on region, CV history, previous ESA treatment, and adjusting on Hb at baseline as continuous covariate. Non-inferiority was declared if the upper bound of the 95% CI is below 1.3.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority (hazard ratio margin of 1.3).</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>p-value for non-inferiority test based on 1-sided significance level.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.924</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.669</ci_lower_limit>
            <ci_upper_limit>1.276</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL in Mean Arterial Pressure (MAP) to the Average MAP Value of Weeks 20 to 28</title>
        <description>Baseline MAP was defined as the MAP value on day 1. If this value was missing, the latest value prior to first study drug administration was used. Mean Arterial Pressure (MAP) is derived as: MAP = (2/3)*DBP + (1/3)*SBP.</description>
        <time_frame>Baseline and weeks 20 to 28</time_frame>
        <population>The analysis population was the FAS, with participants who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL in Mean Arterial Pressure (MAP) to the Average MAP Value of Weeks 20 to 28</title>
          <description>Baseline MAP was defined as the MAP value on day 1. If this value was missing, the latest value prior to first study drug administration was used. Mean Arterial Pressure (MAP) is derived as: MAP = (2/3)*DBP + (1/3)*SBP.</description>
          <population>The analysis population was the FAS, with participants who had available data.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="401"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.739" lower_limit="-1.600" upper_limit="0.123"/>
                    <measurement group_id="O2" value="-0.160" lower_limit="-0.997" upper_limit="0.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The model includes treatment arm, region, CV History, previous ESA treatment, visits and visit by treatment as categorical variables, and baseline MAP, baseline Hb as continuous variables.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.308</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>-0.579</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.694</ci_lower_limit>
            <ci_upper_limit>0.536</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Occurrence of an Increase in Blood Pressure</title>
        <description>Increase in Blood Pressure was defined as either: SBP ≥ 170 mmHg and an increase from BL ≥ 20 mmHg, or as: DBP ≥ 100 mmHg and an increase from BL ≥ 15 mmHg. Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
        <time_frame>Weeks 1 to 36</time_frame>
        <population>The analysis population was the FAS, with participants who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Occurrence of an Increase in Blood Pressure</title>
          <description>Increase in Blood Pressure was defined as either: SBP ≥ 170 mmHg and an increase from BL ≥ 20 mmHg, or as: DBP ≥ 100 mmHg and an increase from BL ≥ 15 mmHg. Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
          <population>The analysis population was the FAS, with participants who had available data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="8.5" upper_limit="14.8"/>
                    <measurement group_id="O2" value="12.0" lower_limit="8.9" upper_limit="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="12.5" upper_limit="19.7"/>
                    <measurement group_id="O2" value="16.2" lower_limit="12.6" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" lower_limit="14.1" upper_limit="28.3"/>
                    <measurement group_id="O2" value="24.1" lower_limit="16.7" upper_limit="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio was calculated using stratified Cox Proportional Hazards regression stratifying on region, CV history, previous ESA treatment, and adjusting on Hb at baseline as continuous covariate. Superiority was declared if the upper bound of the 95% CI is lower than 1.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.582</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.915</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.668</ci_lower_limit>
            <ci_upper_limit>1.254</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Hb Response During Weeks 28 and 36 Regardless of Use of Rescue Therapy</title>
        <description>Hb response was defined as mean Hb during weeks 28 to 36 within the target range of 10.0 to 12.0 g/dL. The percentages and 95% CI are unadjusted, the exact method of Clopper-Pearson was used for 95% CI.</description>
        <time_frame>Weeks 28 to 36</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Hb Response During Weeks 28 and 36 Regardless of Use of Rescue Therapy</title>
          <description>Hb response was defined as mean Hb during weeks 28 to 36 within the target range of 10.0 to 12.0 g/dL. The percentages and 95% CI are unadjusted, the exact method of Clopper-Pearson was used for 95% CI.</description>
          <population>The analysis population was the FAS.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1" lower_limit="79.1" upper_limit="86.5"/>
                    <measurement group_id="O2" value="82.1" lower_limit="78.1" upper_limit="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A generalized linear model was used to estimate the difference in response rates between the arms, as an approximation for the Miettinen and Nurminen method, adjusting for following covariates: region, previous ESA treatment, cardiovascular history and baseline Hb as categorical variables.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.609</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level</p_value_desc>
            <method>Miettinen and Nurminen method</method>
            <param_type>Difference of Percentages</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>6.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL in Hb to Each Postdosing Time Point</title>
        <description>Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dose).</description>
        <time_frame>Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18,20, 22, 24, 26, 28, 30, 32, 34, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72,76, 80, 84, 88, 92, 96, 100, and 104</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL in Hb to Each Postdosing Time Point</title>
          <description>Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dose).</description>
          <population>The analysis population was the FAS.</population>
          <units>g/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hb Change From BL to Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="407"/>
                    <count group_id="O2" value="411"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.232" lower_limit="0.164" upper_limit="0.300"/>
                    <measurement group_id="O2" value="0.068" lower_limit="0.000" upper_limit="0.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="401"/>
                    <count group_id="O2" value="411"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.496" lower_limit="0.420" upper_limit="0.572"/>
                    <measurement group_id="O2" value="0.054" lower_limit="-0.022" upper_limit="0.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="394"/>
                    <count group_id="O2" value="408"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.633" lower_limit="0.552" upper_limit="0.714"/>
                    <measurement group_id="O2" value="0.071" lower_limit="-0.008" upper_limit="0.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="399"/>
                    <count group_id="O2" value="413"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.803" lower_limit="0.715" upper_limit="0.891"/>
                    <measurement group_id="O2" value="0.095" lower_limit="0.009" upper_limit="0.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="399"/>
                    <count group_id="O2" value="407"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.723" lower_limit="0.633" upper_limit="0.812"/>
                    <measurement group_id="O2" value="-0.045" lower_limit="-0.133" upper_limit="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="391"/>
                    <count group_id="O2" value="405"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.868" lower_limit="0.776" upper_limit="0.959"/>
                    <measurement group_id="O2" value="0.138" lower_limit="0.048" upper_limit="0.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="389"/>
                    <count group_id="O2" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.698" lower_limit="0.606" upper_limit="0.791"/>
                    <measurement group_id="O2" value="-0.031" lower_limit="-0.122" upper_limit="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="393"/>
                    <count group_id="O2" value="402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.816" lower_limit="0.724" upper_limit="0.907"/>
                    <measurement group_id="O2" value="0.116" lower_limit="0.026" upper_limit="0.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="409"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.640" lower_limit="0.546" upper_limit="0.735"/>
                    <measurement group_id="O2" value="-0.019" lower_limit="-0.111" upper_limit="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="384"/>
                    <count group_id="O2" value="399"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.732" lower_limit="0.634" upper_limit="0.830"/>
                    <measurement group_id="O2" value="0.139" lower_limit="0.043" upper_limit="0.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="383"/>
                    <count group_id="O2" value="400"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.508" lower_limit="0.408" upper_limit="0.608"/>
                    <measurement group_id="O2" value="0.005" lower_limit="-0.093" upper_limit="0.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="381"/>
                    <count group_id="O2" value="401"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.613" lower_limit="0.511" upper_limit="0.716"/>
                    <measurement group_id="O2" value="0.244" lower_limit="0.144" upper_limit="0.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="378"/>
                    <count group_id="O2" value="395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.380" lower_limit="0.283" upper_limit="0.477"/>
                    <measurement group_id="O2" value="0.017" lower_limit="-0.078" upper_limit="0.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="376"/>
                    <count group_id="O2" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.501" lower_limit="0.405" upper_limit="0.596"/>
                    <measurement group_id="O2" value="0.217" lower_limit="0.124" upper_limit="0.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="370"/>
                    <count group_id="O2" value="395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.266" lower_limit="0.170" upper_limit="0.363"/>
                    <measurement group_id="O2" value="0.069" lower_limit="-0.025" upper_limit="0.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="362"/>
                    <count group_id="O2" value="388"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.262" lower_limit="0.168" upper_limit="0.356"/>
                    <measurement group_id="O2" value="0.075" lower_limit="-0.017" upper_limit="0.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="359"/>
                    <count group_id="O2" value="387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.316" lower_limit="0.220" upper_limit="0.412"/>
                    <measurement group_id="O2" value="0.073" lower_limit="-0.020" upper_limit="0.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="360"/>
                    <count group_id="O2" value="388"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.549" lower_limit="0.452" upper_limit="0.647"/>
                    <measurement group_id="O2" value="0.342" lower_limit="0.248" upper_limit="0.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="352"/>
                    <count group_id="O2" value="380"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.333" lower_limit="0.236" upper_limit="0.429"/>
                    <measurement group_id="O2" value="0.106" lower_limit="0.013" upper_limit="0.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="346"/>
                    <count group_id="O2" value="376"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.310" lower_limit="0.211" upper_limit="0.409"/>
                    <measurement group_id="O2" value="0.111" lower_limit="0.016" upper_limit="0.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 34</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="342"/>
                    <count group_id="O2" value="374"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.364" lower_limit="0.268" upper_limit="0.460"/>
                    <measurement group_id="O2" value="0.084" lower_limit="-0.007" upper_limit="0.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="339"/>
                    <count group_id="O2" value="373"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.482" lower_limit="0.382" upper_limit="0.581"/>
                    <measurement group_id="O2" value="0.225" lower_limit="0.130" upper_limit="0.320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="336"/>
                    <count group_id="O2" value="373"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.199" lower_limit="0.095" upper_limit="0.304"/>
                    <measurement group_id="O2" value="0.064" lower_limit="-0.036" upper_limit="0.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="328"/>
                    <count group_id="O2" value="367"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.335" lower_limit="0.221" upper_limit="0.448"/>
                    <measurement group_id="O2" value="0.252" lower_limit="0.145" upper_limit="0.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="323"/>
                    <count group_id="O2" value="365"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.158" lower_limit="0.047" upper_limit="0.270"/>
                    <measurement group_id="O2" value="0.131" lower_limit="0.027" upper_limit="0.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="308"/>
                    <count group_id="O2" value="363"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.385" lower_limit="0.273" upper_limit="0.496"/>
                    <measurement group_id="O2" value="0.186" lower_limit="0.082" upper_limit="0.290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="311"/>
                    <count group_id="O2" value="360"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.217" lower_limit="0.104" upper_limit="0.329"/>
                    <measurement group_id="O2" value="0.069" lower_limit="-0.035" upper_limit="0.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="299"/>
                    <count group_id="O2" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.368" lower_limit="0.256" upper_limit="0.479"/>
                    <measurement group_id="O2" value="0.171" lower_limit="0.067" upper_limit="0.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.181" lower_limit="0.067" upper_limit="0.295"/>
                    <measurement group_id="O2" value="-0.093" lower_limit="-0.198" upper_limit="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="349"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.306" lower_limit="0.195" upper_limit="0.416"/>
                    <measurement group_id="O2" value="0.100" lower_limit="-0.002" upper_limit="0.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="284"/>
                    <count group_id="O2" value="339"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.109" lower_limit="-0.005" upper_limit="0.222"/>
                    <measurement group_id="O2" value="-0.009" lower_limit="-0.113" upper_limit="0.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="278"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.401" lower_limit="0.280" upper_limit="0.521"/>
                    <measurement group_id="O2" value="0.189" lower_limit="0.079" upper_limit="0.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 80</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="327"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.087" lower_limit="-0.028" upper_limit="0.203"/>
                    <measurement group_id="O2" value="-0.015" lower_limit="-0.120" upper_limit="0.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="270"/>
                    <count group_id="O2" value="328"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.318" lower_limit="0.199" upper_limit="0.438"/>
                    <measurement group_id="O2" value="0.126" lower_limit="0.017" upper_limit="0.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 88</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="258"/>
                    <count group_id="O2" value="326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026" lower_limit="-0.091" upper_limit="0.144"/>
                    <measurement group_id="O2" value="-0.018" lower_limit="-0.124" upper_limit="0.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 92</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.357" lower_limit="0.232" upper_limit="0.483"/>
                    <measurement group_id="O2" value="0.154" lower_limit="0.041" upper_limit="0.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.126" lower_limit="0.010" upper_limit="0.242"/>
                    <measurement group_id="O2" value="-0.058" lower_limit="-0.163" upper_limit="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.302" lower_limit="0.175" upper_limit="0.430"/>
                    <measurement group_id="O2" value="0.138" lower_limit="0.024" upper_limit="0.253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="240"/>
                    <count group_id="O2" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.232" lower_limit="0.100" upper_limit="0.363"/>
                    <measurement group_id="O2" value="0.133" lower_limit="0.014" upper_limit="0.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 1- The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.164</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.072</ci_lower_limit>
            <ci_upper_limit>0.256</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 2- The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.443</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.339</ci_lower_limit>
            <ci_upper_limit>0.546</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 3 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.561</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.451</ci_lower_limit>
            <ci_upper_limit>0.672</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.708</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.588</ci_lower_limit>
            <ci_upper_limit>0.828</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 5 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.768</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.645</ci_lower_limit>
            <ci_upper_limit>0.890</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 6 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.729</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.604</ci_lower_limit>
            <ci_upper_limit>0.855</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 7 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.729</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.603</ci_lower_limit>
            <ci_upper_limit>0.856</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.700</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.574</ci_lower_limit>
            <ci_upper_limit>0.826</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 10 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.659</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.530</ci_lower_limit>
            <ci_upper_limit>0.788</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.593</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.459</ci_lower_limit>
            <ci_upper_limit>0.727</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 14 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.503</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.366</ci_lower_limit>
            <ci_upper_limit>0.640</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 16 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.369</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.229</ci_lower_limit>
            <ci_upper_limit>0.510</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 18 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.363</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.230</ci_lower_limit>
            <ci_upper_limit>0.496</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 20 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.284</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.154</ci_lower_limit>
            <ci_upper_limit>0.414</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 22 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.003</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.197</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.065</ci_lower_limit>
            <ci_upper_limit>0.329</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.004</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.187</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.059</ci_lower_limit>
            <ci_upper_limit>0.316</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 26 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.243</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.113</ci_lower_limit>
            <ci_upper_limit>0.373</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 28 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.002</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.207</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.074</ci_lower_limit>
            <ci_upper_limit>0.340</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 30 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.227</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.096</ci_lower_limit>
            <ci_upper_limit>0.358</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 32 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>p-value for superiority test based on 2-sided significance level.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.199</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.064</ci_lower_limit>
            <ci_upper_limit>0.334</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 34 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.279</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.150</ci_lower_limit>
            <ci_upper_limit>0.409</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 36- The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.256</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.121</ci_lower_limit>
            <ci_upper_limit>0.391</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 40 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.060</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.136</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.006</ci_lower_limit>
            <ci_upper_limit>0.277</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 44 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.293</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.082</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.071</ci_lower_limit>
            <ci_upper_limit>0.236</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.723</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.027</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.123</ci_lower_limit>
            <ci_upper_limit>0.177</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.009</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.199</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.049</ci_lower_limit>
            <ci_upper_limit>0.348</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 56 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.056</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.147</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.004</ci_lower_limit>
            <ci_upper_limit>0.298</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 60 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.010</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.196</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.047</ci_lower_limit>
            <ci_upper_limit>0.346</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 64 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.275</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.123</ci_lower_limit>
            <ci_upper_limit>0.427</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 68 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.006</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.206</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.059</ci_lower_limit>
            <ci_upper_limit>0.353</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 72 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.127</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.118</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.033</ci_lower_limit>
            <ci_upper_limit>0.269</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 76 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.010</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.211</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.051</ci_lower_limit>
            <ci_upper_limit>0.371</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 80 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.191</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.102</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.051</ci_lower_limit>
            <ci_upper_limit>0.255</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 84 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.018</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.192</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.033</ci_lower_limit>
            <ci_upper_limit>0.351</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 88 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.576</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.044</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.111</ci_lower_limit>
            <ci_upper_limit>0.200</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 92 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.017</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.203</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.369</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 96 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.019</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.184</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.031</ci_lower_limit>
            <ci_upper_limit>0.338</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 100 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.056</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.164</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.004</ci_lower_limit>
            <ci_upper_limit>0.333</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 104 - The model included treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline Hb as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.267</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.099</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.076</ci_lower_limit>
            <ci_upper_limit>0.273</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hb Level Averaged Over Weeks 28 to 36, 44 to 52, and 96 to 104 Without Use of Rescue Therapy</title>
        <description>Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dose). Averaged Hb values over weeks 28-36, weeks 44-52 and weeks 96-104 are observed values.</description>
        <time_frame>Weeks 28 to 36, 44 to 52, and 96 to 104</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Hb Level Averaged Over Weeks 28 to 36, 44 to 52, and 96 to 104 Without Use of Rescue Therapy</title>
          <description>Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dose). Averaged Hb values over weeks 28-36, weeks 44-52 and weeks 96-104 are observed values.</description>
          <population>The analysis population was the FAS.</population>
          <units>g/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average Hb Over Weeks 28-36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="362"/>
                    <count group_id="O2" value="393"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.183" lower_limit="11.100" upper_limit="11.265"/>
                    <measurement group_id="O2" value="10.946" lower_limit="10.867" upper_limit="11.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Hb Over Weeks 44-52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="370"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.099" lower_limit="11.009" upper_limit="11.189"/>
                    <measurement group_id="O2" value="10.994" lower_limit="10.909" upper_limit="11.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Hb Over Weeks 96-104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="317"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.007" lower_limit="10.904" upper_limit="11.110"/>
                    <measurement group_id="O2" value="10.858" lower_limit="10.766" upper_limit="10.950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Weeks 28-36 - The model includes treatment arm, region, CV History, previous ESA treatment, visits and visit by treatment as categorical variables and baseline Hb as continuous variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.237</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.127</ci_lower_limit>
            <ci_upper_limit>0.347</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Weeks 44-52 - The model includes treatment arm, region, CV History, previous ESA treatment, visits and visit by treatment as categorical variables and baseline Hb as continuous variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.086</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.105</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.015</ci_lower_limit>
            <ci_upper_limit>0.225</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Weeks 96-104 - The model includes treatment arm, region, CV History, previous ESA treatment, visits and visit by treatment as categorical variables and baseline Hb as continuous variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.031</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.149</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.014</ci_lower_limit>
            <ci_upper_limit>0.284</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL in Hb to the Average of Weeks 28 to 36, 44 to 52, and 96 to 104 Regardless of the Use of Rescue Therapy</title>
        <description>Change from baseline to the average Hb are observed values. Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dose).</description>
        <time_frame>Baseline and weeks 28 to 36, 44 to 52, and 96 to 104</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL in Hb to the Average of Weeks 28 to 36, 44 to 52, and 96 to 104 Regardless of the Use of Rescue Therapy</title>
          <description>Change from baseline to the average Hb are observed values. Baseline Hb was defined as the mean of four latest central laboratory Hb values prior or on the same date as first study drug intake (pre-dose).</description>
          <population>The analysis population was the FAS.</population>
          <units>g/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hb Change From BL to Weeks 28-36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="364"/>
                    <count group_id="O2" value="393"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.408" lower_limit="0.325" upper_limit="0.491"/>
                    <measurement group_id="O2" value="0.173" lower_limit="0.093" upper_limit="0.252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Weeks 44-52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="331"/>
                    <count group_id="O2" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.298" lower_limit="0.203" upper_limit="0.394"/>
                    <measurement group_id="O2" value="0.194" lower_limit="0.104" upper_limit="0.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb Change From BL to Weeks 96-104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="318"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.225" lower_limit="0.119" upper_limit="0.331"/>
                    <measurement group_id="O2" value="0.076" lower_limit="-0.020" upper_limit="0.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Weeks 28-36 - The model includes treatment arm, region, CV History, previous ESA treatment, visits and visit by treatment as categorical variables and baseline Hb as continuous variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.235</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.125</ci_lower_limit>
            <ci_upper_limit>0.346</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Weeks 44-52 - The model includes treatment arm, region, CV History, previous ESA treatment, visits and visit by treatment as categorical variables and baseline Hb as continuous variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.110</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.104</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.024</ci_lower_limit>
            <ci_upper_limit>0.232</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Weeks 96-104 - The model includes treatment arm, region, CV History, previous ESA treatment, visits and visit by treatment as categorical variables and baseline Hb as continuous variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.036</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.149</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.010</ci_lower_limit>
            <ci_upper_limit>0.288</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Hb Values ≥ 10 g/dL in Weeks 28 to 36, 44 to 52, and 96 to 104 Without Use of Rescue Therapy</title>
        <description>Percentage for each participant was calculated as Number of Hb values &gt;= 10.0 g/dL / Total number of Hb values*100 in weeks 28 to 36, 44 to 52 and 96 to 104 without use of rescue therapy within 6 weeks prior to and during the 8 week evaluation period.</description>
        <time_frame>Weeks 28-36, 44-52 and 96-104</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Hb Values ≥ 10 g/dL in Weeks 28 to 36, 44 to 52, and 96 to 104 Without Use of Rescue Therapy</title>
          <description>Percentage for each participant was calculated as Number of Hb values &gt;= 10.0 g/dL / Total number of Hb values*100 in weeks 28 to 36, 44 to 52 and 96 to 104 without use of rescue therapy within 6 weeks prior to and during the 8 week evaluation period.</description>
          <population>The analysis population was the FAS.</population>
          <units>percentage of Hb values</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weeks 28-36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="364"/>
                    <count group_id="O2" value="393"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.002" spread="18.320"/>
                    <measurement group_id="O2" value="87.286" spread="25.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 44-52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="331"/>
                    <count group_id="O2" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.421" spread="24.267"/>
                    <measurement group_id="O2" value="86.914" spread="25.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 96-104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="318"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.858" spread="24.708"/>
                    <measurement group_id="O2" value="83.543" spread="30.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Hb Values Within 10.0 to 12.0 g/dL in Weeks 28 to 36, 44 to 52, and 96 to 104 Without Use of Rescue Therapy</title>
        <description>Percentage for each participant was calculated as Number of Hb values within 10.0-12.0 g/dL / Total number of Hb values*100 in weeks 28 to 36, 44 to 52 and 96 to 104 without use of rescue therapy within 6 weeks prior to and during the 8 week evaluation period.</description>
        <time_frame>Weeks 28-36, 44-52 and 96-104</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Hb Values Within 10.0 to 12.0 g/dL in Weeks 28 to 36, 44 to 52, and 96 to 104 Without Use of Rescue Therapy</title>
          <description>Percentage for each participant was calculated as Number of Hb values within 10.0-12.0 g/dL / Total number of Hb values*100 in weeks 28 to 36, 44 to 52 and 96 to 104 without use of rescue therapy within 6 weeks prior to and during the 8 week evaluation period.</description>
          <population>The analysis population was the FAS.</population>
          <units>percentage of Hb values</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weeks 28-36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="364"/>
                    <count group_id="O2" value="393"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.326" spread="28.175"/>
                    <measurement group_id="O2" value="76.098" spread="28.991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 44-52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="331"/>
                    <count group_id="O2" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.891" spread="31.047"/>
                    <measurement group_id="O2" value="74.634" spread="30.589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 96-104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="318"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.522" spread="30.378"/>
                    <measurement group_id="O2" value="73.690" spread="33.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospitalizations</title>
        <description>The number of hospitalizations per participant were calculated during the Efficacy Emergent Period. The Efficacy Emergent Period was defined as the evaluation period from the Analysis date of first dose intake up to EOT Visit or last non-missing Hb assessment (for participants who died during the treatment period). It included all Non-Hemodialysis (HD) hospitalizations. The HD days were not counted as hospitalizations, even when performed overnight.</description>
        <time_frame>Baseline to End of Treatment (EOT) (Up to week 104)</time_frame>
        <population>The analysis population was the FAS, with participants who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospitalizations</title>
          <description>The number of hospitalizations per participant were calculated during the Efficacy Emergent Period. The Efficacy Emergent Period was defined as the evaluation period from the Analysis date of first dose intake up to EOT Visit or last non-missing Hb assessment (for participants who died during the treatment period). It included all Non-Hemodialysis (HD) hospitalizations. The HD days were not counted as hospitalizations, even when performed overnight.</description>
          <population>The analysis population was the FAS, with participants who had available data.</population>
          <units>Hospitalizations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.3"/>
                    <measurement group_id="O2" value="0.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Hospitalization Per Year</title>
        <description>The number of days of hospitalizations per year was calculated as the sum of the durations of all non-HD hospitalizations in days (Date of discharge - Date of admission + 1)] / (duration of efficacy emergent period in days / 365.25). In case of missing dates, the hospitalization duration was imputed by the average duration per stay derived from the participants with non-missing duration within the same treatment group.</description>
        <time_frame>Baseline to EOT (Up to week 104)</time_frame>
        <population>The analysis population was the FAS, with participants who had available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Hospitalization Per Year</title>
          <description>The number of days of hospitalizations per year was calculated as the sum of the durations of all non-HD hospitalizations in days (Date of discharge - Date of admission + 1)] / (duration of efficacy emergent period in days / 365.25). In case of missing dates, the hospitalization duration was imputed by the average duration per stay derived from the participants with non-missing duration within the same treatment group.</description>
          <population>The analysis population was the FAS, with participants who had available data.</population>
          <units>Days per year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.186" spread="34.121"/>
                    <measurement group_id="O2" value="7.868" spread="22.948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Hospitalization</title>
        <description>Time to first hospitalization in years was defined in years as: (First event date during the Efficacy Emergent Period - Analysis date of First dose intake +1)/365.25, and the 'First event date' was defined as 'Date of first Admission and 'Analysis Date of first dose intake. For participants without hospitalization, the time to censoring was calculated as: (Date of End of Efficacy Emergent Period - Analysis Date of first dose intake + 1) / 365.25. Date of End of Efficacy Emergent Period was defined as as the treatment period up to the EOT visit. For participants who have experienced more than one hospitalization, only their first event following study treatment was used. Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
        <time_frame>Baseline to EOT (Up to week 104)</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Hospitalization</title>
          <description>Time to first hospitalization in years was defined in years as: (First event date during the Efficacy Emergent Period - Analysis date of First dose intake +1)/365.25, and the 'First event date' was defined as 'Date of first Admission and 'Analysis Date of first dose intake. For participants without hospitalization, the time to censoring was calculated as: (Date of End of Efficacy Emergent Period - Analysis Date of first dose intake + 1) / 365.25. Date of End of Efficacy Emergent Period was defined as as the treatment period up to the EOT visit. For participants who have experienced more than one hospitalization, only their first event following study treatment was used. Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
          <population>The analysis population was the FAS.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 0.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" lower_limit="15.5" upper_limit="23.3"/>
                    <measurement group_id="O2" value="18.3" lower_limit="14.6" upper_limit="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" lower_limit="27.3" upper_limit="36.6"/>
                    <measurement group_id="O2" value="32.7" lower_limit="28.2" upper_limit="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5" lower_limit="38.5" upper_limit="48.6"/>
                    <measurement group_id="O2" value="41.9" lower_limit="37.0" upper_limit="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" lower_limit="47.5" upper_limit="57.8"/>
                    <measurement group_id="O2" value="48.3" lower_limit="43.3" upper_limit="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio was calculated using stratified Cox Proportional Hazards regression stratifying on region, CV history, previous ESA treatment and adjusting on Hb at baseline as continuous covariate. Superiority was declared if the upper bound of the 95% CI was below 1.0.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.164</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.154</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.943</ci_lower_limit>
            <ci_upper_limit>1.411</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Use of Rescue Therapy</title>
        <description>Rescue therapy was defined as red blood cell (RBC) transfusion for both treatment groups and ESA for roxadustat participants. Only rescue medication that was started during the study treatment and up to end of efficacy emergent period was taken into account and considered as use of rescue medication. For participants who have experienced more than one use of rescue therapy, only their first event following study treatment was used. Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
        <time_frame>Baseline to EOT (Up to week 104)</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Use of Rescue Therapy</title>
          <description>Rescue therapy was defined as red blood cell (RBC) transfusion for both treatment groups and ESA for roxadustat participants. Only rescue medication that was started during the study treatment and up to end of efficacy emergent period was taken into account and considered as use of rescue medication. For participants who have experienced more than one use of rescue therapy, only their first event following study treatment was used. Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
          <population>The analysis population was the FAS.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 0.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="2.0" upper_limit="5.8"/>
                    <measurement group_id="O2" value="3.2" lower_limit="1.5" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="5.4" upper_limit="11.1"/>
                    <measurement group_id="O2" value="8.4" lower_limit="5.6" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" lower_limit="8.1" upper_limit="14.8"/>
                    <measurement group_id="O2" value="10.9" lower_limit="7.8" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="9.3" upper_limit="16.4"/>
                    <measurement group_id="O2" value="14.4" lower_limit="10.8" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio was calculated using stratified Cox Proportional Hazards regression stratifying on region, CV history, previous ESA treatment and adjusting on Hb at baseline as continuous covariate. Superiority was declared if the upper bound of the 95% CI was below 1.0.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.917</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.979</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.656</ci_lower_limit>
            <ci_upper_limit>1.462</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First RBC Transfusion</title>
        <description>For participants who have experienced more than one RBC transfusion, only their first event following study treatment was used. For RBC transfusions, when the number of units was not given but the volume transfused was, the number of units were estimated by volume transfused/250 mL (for transfusion of packed cell units) or volume transfused/500 mL (for transfusion of full blood). Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
        <time_frame>Baseline to EOT (Up to week 104)</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First RBC Transfusion</title>
          <description>For participants who have experienced more than one RBC transfusion, only their first event following study treatment was used. For RBC transfusions, when the number of units was not given but the volume transfused was, the number of units were estimated by volume transfused/250 mL (for transfusion of packed cell units) or volume transfused/500 mL (for transfusion of full blood). Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
          <population>The analysis population was the FAS.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 0.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="1.8" upper_limit="5.5"/>
                    <measurement group_id="O2" value="3.2" lower_limit="1.5" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="4.7" upper_limit="10.1"/>
                    <measurement group_id="O2" value="8.4" lower_limit="5.6" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="6.9" upper_limit="13.2"/>
                    <measurement group_id="O2" value="10.9" lower_limit="7.8" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" lower_limit="8.0" upper_limit="14.9"/>
                    <measurement group_id="O2" value="14.4" lower_limit="10.8" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio was calculated using stratified Cox Proportional Hazards regression stratifying on region, CV history, previous ESA treatment, and adjusting on Hb at baseline as continuous covariate. Superiority was declared if the upper bound of the 95% CI was below 1.0.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.501</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.867</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.573</ci_lower_limit>
            <ci_upper_limit>1.313</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Monthly Number of RBC Packs Per Participant</title>
        <description>During efficacy emergent period, the mean monthly number of RBC packs was calculated as the sum of blood volume and units transfused between the first dose and up to the last dose in the period divided by duration of efficacy emergent period (in days) divided by 28 days. Participants without medication records of RBC have their number of RBC packs and volume set to 0.</description>
        <time_frame>Baseline to EOT (Up to week 104)</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Monthly Number of RBC Packs Per Participant</title>
          <description>During efficacy emergent period, the mean monthly number of RBC packs was calculated as the sum of blood volume and units transfused between the first dose and up to the last dose in the period divided by duration of efficacy emergent period (in days) divided by 28 days. Participants without medication records of RBC have their number of RBC packs and volume set to 0.</description>
          <population>The analysis population was the FAS.</population>
          <units>RBC packs per month</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026" lower_limit="0.01" upper_limit="0.04"/>
                    <measurement group_id="O2" value="0.032" lower_limit="0.02" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The model included treatment arm, region, CV History, previous ESA treatment as categorical variables and baseline Hb as continuous variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.507</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LSM Difference</param_type>
            <param_value>-0.006</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Monthly Volume of RBC Transfusion Per Participant</title>
        <description>During Efficacy Emergent Period, the mean monthly volume of blood transfused was calculated as the sum of blood volume and units transfused between the first dose and up to the last dose in the period divided by duration of efficacy emergent period (in days) divided by 28 days. The Efficacy Emergent Period was defined as the evaluation period from the Analysis date of first dose intake up to EOT Visit or last non-missing Hb assessment (for participants who died during the treatment period).</description>
        <time_frame>Baseline to EOT (Up to week 104)</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Monthly Volume of RBC Transfusion Per Participant</title>
          <description>During Efficacy Emergent Period, the mean monthly volume of blood transfused was calculated as the sum of blood volume and units transfused between the first dose and up to the last dose in the period divided by duration of efficacy emergent period (in days) divided by 28 days. The Efficacy Emergent Period was defined as the evaluation period from the Analysis date of first dose intake up to EOT Visit or last non-missing Hb assessment (for participants who died during the treatment period).</description>
          <population>The analysis population was the FAS.</population>
          <units>mL per month</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.061" lower_limit="2.82" upper_limit="9.30"/>
                    <measurement group_id="O2" value="5.929" lower_limit="2.74" upper_limit="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The model included treatment arm, region, CV History, previous ESA treatment as categorical variables and baseline Hb as continuous variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.949</p_value>
            <method>ANCOVA</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.132</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.90</ci_lower_limit>
            <ci_upper_limit>4.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Use of IV Iron Supplementation</title>
        <description>For participants who have received more than one IV iron, only their first event following study treatment was used. Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
        <time_frame>Baseline to EOT (Up to week 104)</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Use of IV Iron Supplementation</title>
          <description>For participants who have received more than one IV iron, only their first event following study treatment was used. Data reported was analyzed by Kaplan-Meier estimate for cumulative proportion and the 95% confidence interval was calculated with Greenwood's formula.</description>
          <population>The analysis population was the FAS.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 0.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="8.1" upper_limit="14.3"/>
                    <measurement group_id="O2" value="33.5" lower_limit="29.0" upper_limit="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="13.5" upper_limit="21.2"/>
                    <measurement group_id="O2" value="44.1" lower_limit="39.3" upper_limit="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6" lower_limit="19.1" upper_limit="28.1"/>
                    <measurement group_id="O2" value="55.0" lower_limit="50.1" upper_limit="59.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="26.0" upper_limit="40.7"/>
                    <measurement group_id="O2" value="59.3" lower_limit="54.4" upper_limit="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio was calculated using stratified Cox Proportional Hazards regression stratifying on region, CV history, previous ESA treatment and adjusting on Hb at baseline as continuous covariate. Superiority was declared if the upper bound of the 95% CI was below 1.0.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.368</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.291</ci_lower_limit>
            <ci_upper_limit>0.465</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Monthly Intravenous (IV) Iron Per Participant During Weeks 37-52 and Weeks 53-104</title>
        <description>Participants with no or missing medication records of IV Iron had their monthly IV Iron use set to 0 mg.</description>
        <time_frame>Weeks 37-52 and weeks 53-104</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Monthly Intravenous (IV) Iron Per Participant During Weeks 37-52 and Weeks 53-104</title>
          <description>Participants with no or missing medication records of IV Iron had their monthly IV Iron use set to 0 mg.</description>
          <population>The analysis population was the FAS.</population>
          <units>mg per month</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weeks 37-52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9" lower_limit="20.9" upper_limit="48.9"/>
                    <measurement group_id="O2" value="70.0" lower_limit="56.9" upper_limit="83.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 53-104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5" lower_limit="31.0" upper_limit="67.9"/>
                    <measurement group_id="O2" value="98.1" lower_limit="81.1" upper_limit="115.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Weeks 37-52 - Participants with no or missing medication records of IV Iron had their monthly IV Iron use set to 0 mg. The model includes treatment arm, region, CV History, previous ESA treatment as categorical variables and baseline Hb as continuous variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LSM Difference</param_type>
            <param_value>-35.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.8</ci_lower_limit>
            <ci_upper_limit>-18.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Weeks 53-104 - Participants with no or missing medication records of IV Iron had their monthly IV Iron use set to 0 mg. The model includes treatment arm, region, CV History, previous ESA treatment as categorical variables and baseline Hb as continuous variable.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LSM Difference</param_type>
            <param_value>-48.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-70.3</ci_lower_limit>
            <ci_upper_limit>-27.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Oral Iron Use Only</title>
        <description>Percentage of participants with/without IV iron only was calculated based on total number of participants within the Efficacy Emergent Period. The Efficacy Emergent Period is defined as the evaluation period from the Analysis date of first dose intake up to EOT Visit or last non-missing Hb assessment (for participants who died during the treatment period).</description>
        <time_frame>Baseline to EOT (Up to week 104)</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Oral Iron Use Only</title>
          <description>Percentage of participants with/without IV iron only was calculated based on total number of participants within the Efficacy Emergent Period. The Efficacy Emergent Period is defined as the evaluation period from the Analysis date of first dose intake up to EOT Visit or last non-missing Hb assessment (for participants who died during the treatment period).</description>
          <population>The analysis population was the FAS.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0"/>
                    <measurement group_id="O2" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL to Each Post-dosing Study Visit in Total Cholesterol</title>
        <description>Baseline assessment was the assessment from Day 1 visit. If baseline value was missing, then the latest screening period value was used as the baseline regardless of fasting status.</description>
        <time_frame>Baseline and weeks 8, 28, 52, 104</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL to Each Post-dosing Study Visit in Total Cholesterol</title>
          <description>Baseline assessment was the assessment from Day 1 visit. If baseline value was missing, then the latest screening period value was used as the baseline regardless of fasting status.</description>
          <population>The analysis population was the FAS.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL to Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="392"/>
                    <count group_id="O2" value="411"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.608" spread="0.889"/>
                    <measurement group_id="O2" value="-0.105" spread="0.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="364"/>
                    <count group_id="O2" value="393"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.641" spread="0.960"/>
                    <measurement group_id="O2" value="-0.135" spread="0.805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="318"/>
                    <count group_id="O2" value="362"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.803" spread="1.027"/>
                    <measurement group_id="O2" value="-0.241" spread="0.906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="247"/>
                    <count group_id="O2" value="307"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.904" spread="1.053"/>
                    <measurement group_id="O2" value="-0.277" spread="1.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL to Each Post-dosing Study Visit in LDL-C/High-density Lipoprotein Cholesterol (HDL-C) Ratio</title>
        <description>Baseline was defined as the value on Day 1. If baseline value was missing, the latest value prior to first study drug administration was used regardless of fasting.</description>
        <time_frame>Baseline and weeks 8, 28, 52, 104</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL to Each Post-dosing Study Visit in LDL-C/High-density Lipoprotein Cholesterol (HDL-C) Ratio</title>
          <description>Baseline was defined as the value on Day 1. If baseline value was missing, the latest value prior to first study drug administration was used regardless of fasting.</description>
          <population>The analysis population was the FAS.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL to Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="390"/>
                    <count group_id="O2" value="411"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.245" spread="0.818"/>
                    <measurement group_id="O2" value="-0.060" spread="0.726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="362"/>
                    <count group_id="O2" value="393"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.155" spread="1.046"/>
                    <measurement group_id="O2" value="-0.057" spread="0.922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                    <count group_id="O2" value="361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.345" spread="0.904"/>
                    <measurement group_id="O2" value="-0.078" spread="0.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="307"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.261" spread="1.167"/>
                    <measurement group_id="O2" value="-0.013" spread="1.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL to Each Postdosing Study Visit in Non-HDL Cholesterol</title>
        <description>Baseline was defined as the value on Day 1. If baseline value was missing, the latest value prior to first study drug administration was used regardless of fasting.</description>
        <time_frame>Baseline and weeks 8, 28, 52, 104</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL to Each Postdosing Study Visit in Non-HDL Cholesterol</title>
          <description>Baseline was defined as the value on Day 1. If baseline value was missing, the latest value prior to first study drug administration was used regardless of fasting.</description>
          <population>The analysis population was the FAS.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL to Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="388"/>
                    <count group_id="O2" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.518" spread="0.823"/>
                    <measurement group_id="O2" value="-0.107" spread="0.701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="360"/>
                    <count group_id="O2" value="391"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.540" spread="0.907"/>
                    <measurement group_id="O2" value="-0.127" spread="0.789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="360"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.700" spread="0.965"/>
                    <measurement group_id="O2" value="-0.229" spread="0.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="245"/>
                    <count group_id="O2" value="304"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.788" spread="1.024"/>
                    <measurement group_id="O2" value="-0.240" spread="1.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL to Each Postdosing Study Visit in Apolipoproteins A1 (ApoA1)</title>
        <description>Baseline was defined as the value on Day 1. If baseline value was missing, the latest value prior to first study drug administration was used regardless of fasting.</description>
        <time_frame>Baseline and weeks 8, 28, 52, 104</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL to Each Postdosing Study Visit in Apolipoproteins A1 (ApoA1)</title>
          <description>Baseline was defined as the value on Day 1. If baseline value was missing, the latest value prior to first study drug administration was used regardless of fasting.</description>
          <population>The analysis population was the FAS.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL to Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="394"/>
                    <count group_id="O2" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.114" spread="0.197"/>
                    <measurement group_id="O2" value="-0.006" spread="0.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="367"/>
                    <count group_id="O2" value="393"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.113" spread="0.217"/>
                    <measurement group_id="O2" value="-0.012" spread="0.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="366"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.097" spread="0.230"/>
                    <measurement group_id="O2" value="-0.013" spread="0.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="309"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.097" spread="0.220"/>
                    <measurement group_id="O2" value="-0.012" spread="0.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL to Each Postdosing Study Visit in Apolipoproteins B (ApoB)</title>
        <description>Baseline was defined as the value on Day 1. If baseline value was missing, the latest value prior to first study drug administration was used regardless of fasting.</description>
        <time_frame>Baseline and weeks 8, 28, 52, 104</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL to Each Postdosing Study Visit in Apolipoproteins B (ApoB)</title>
          <description>Baseline was defined as the value on Day 1. If baseline value was missing, the latest value prior to first study drug administration was used regardless of fasting.</description>
          <population>The analysis population was the FAS.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL to Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="394"/>
                    <count group_id="O2" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.03" spread="18.49"/>
                    <measurement group_id="O2" value="1.00" spread="14.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="366"/>
                    <count group_id="O2" value="393"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.18" spread="20.39"/>
                    <measurement group_id="O2" value="-0.12" spread="16.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="366"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.18" spread="20.67"/>
                    <measurement group_id="O2" value="-0.01" spread="18.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="309"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.50" spread="24.94"/>
                    <measurement group_id="O2" value="-0.01" spread="20.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL to Each Postdosing Study Visit in ApoB/ApoA1 Ratio</title>
        <description>Baseline was defined as the value on Day 1. If baseline value was missing, the latest value prior to first study drug administration was used.</description>
        <time_frame>Baseline and weeks 8, 28, 52, 104</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL to Each Postdosing Study Visit in ApoB/ApoA1 Ratio</title>
          <description>Baseline was defined as the value on Day 1. If baseline value was missing, the latest value prior to first study drug administration was used.</description>
          <population>The analysis population was the FAS.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL to Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="393"/>
                    <count group_id="O2" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.037" spread="0.147"/>
                    <measurement group_id="O2" value="0.013" spread="0.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="365"/>
                    <count group_id="O2" value="392"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.034" spread="0.177"/>
                    <measurement group_id="O2" value="0.002" spread="0.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="318"/>
                    <count group_id="O2" value="365"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.051" spread="0.191"/>
                    <measurement group_id="O2" value="0.007" spread="0.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL to Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="309"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.062" spread="0.210"/>
                    <measurement group_id="O2" value="0.007" spread="0.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mean LDL Cholesterol &lt; 100 mg/dL Over Weeks 12 to 28</title>
        <description>Missing category for Fasting Only includes non-fasting participants and the participants with missing values.</description>
        <time_frame>Weeks 12 to 28</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mean LDL Cholesterol &lt; 100 mg/dL Over Weeks 12 to 28</title>
          <description>Missing category for Fasting Only includes non-fasting participants and the participants with missing values.</description>
          <population>The analysis population was the FAS.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes [Regardless of Fasting Status]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275"/>
                    <measurement group_id="O2" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No [Regardless of Fasting Status]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing [Regardless of Fasting Status]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes [Fasting Only]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No [Fasting Only]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing [Fasting Only]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                    <measurement group_id="O2" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With CKD Who Achieved Antihypertensive Treatment Goal</title>
        <description>Achieved antihypertensive treatment goal was defined as SBP &lt; 140 mmHg and DBP &lt; 90 mmHg over an evaluation period based on the average of available values in weeks 12-28 (pre-dialysis).</description>
        <time_frame>Weeks 12 to 28</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With CKD Who Achieved Antihypertensive Treatment Goal</title>
          <description>Achieved antihypertensive treatment goal was defined as SBP &lt; 140 mmHg and DBP &lt; 90 mmHg over an evaluation period based on the average of available values in weeks 12-28 (pre-dialysis).</description>
          <population>The analysis population was the FAS.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Antihypertensive Treatment Achievement - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264"/>
                    <measurement group_id="O2" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antihypertensive Treatment Achievement - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antihypertensive Treatment Achievement-Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL to the Average of Weeks 12 to 28 in SF-36 Physical Component Score (PCS)</title>
        <description>Baseline SF-36 PCS was defined as the SF-36 PCS value on Day 1. SF-36 contains 36-item that measures 8 scales with scores ranging from 0-100: physical functioning (PF); role limitations due to physical health problems (RP); bodily pain (BP); social functioning (SF); general health perceptions (GH); role limitations due to emotional problems (RE); vitality, energy or fatigue (VT); and mental health (MH). These scores are normed to the US population (norm-based scoring had very little impact on results when data was collected in Western European countries) to have a mean of 50 and standard deviation of 10. The PCS was calculated based on all 8 scales and ranges from 5.02-79.78. For each of these above scales, higher scores always indicating better health status.</description>
        <time_frame>Baseline and weeks 12 to 28</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL to the Average of Weeks 12 to 28 in SF-36 Physical Component Score (PCS)</title>
          <description>Baseline SF-36 PCS was defined as the SF-36 PCS value on Day 1. SF-36 contains 36-item that measures 8 scales with scores ranging from 0-100: physical functioning (PF); role limitations due to physical health problems (RP); bodily pain (BP); social functioning (SF); general health perceptions (GH); role limitations due to emotional problems (RE); vitality, energy or fatigue (VT); and mental health (MH). These scores are normed to the US population (norm-based scoring had very little impact on results when data was collected in Western European countries) to have a mean of 50 and standard deviation of 10. The PCS was calculated based on all 8 scales and ranges from 5.02-79.78. For each of these above scales, higher scores always indicating better health status.</description>
          <population>The analysis population was the FAS.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="384"/>
                <count group_id="O2" value="404"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.560" lower_limit="-0.029" upper_limit="1.148"/>
                    <measurement group_id="O2" value="0.039" lower_limit="-0.528" upper_limit="0.605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The model includes treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline SF-36 PCS, baseline Hb, as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.161</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.521</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.208</ci_lower_limit>
            <ci_upper_limit>1.250</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL to the Average of Weeks 12 to 28 in Anemia Subscale (AnS) (&quot;Additional Concerns&quot;) of Functional Assessment of Cancer Therapy-Anemia (FACT-An) Score</title>
        <description>Baseline FACT-An AnS was defined as the FACT-An AnS value on Day 1. Together with the Functional Assessment of Cancer Therapy - General (FACT-G), the Anemia Subscale (AnS) is referred to as the FACT-An Total. The AnS scale contains 13 fatigue specific items (the Fatigue Score) plus 7 items related to anemia. The Anemia AnS score range is 0 to 80. For the above score, a higher score indicates better QoL.</description>
        <time_frame>Baseline and weeks 12 to 28</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL to the Average of Weeks 12 to 28 in Anemia Subscale (AnS) (&quot;Additional Concerns&quot;) of Functional Assessment of Cancer Therapy-Anemia (FACT-An) Score</title>
          <description>Baseline FACT-An AnS was defined as the FACT-An AnS value on Day 1. Together with the Functional Assessment of Cancer Therapy - General (FACT-G), the Anemia Subscale (AnS) is referred to as the FACT-An Total. The AnS scale contains 13 fatigue specific items (the Fatigue Score) plus 7 items related to anemia. The Anemia AnS score range is 0 to 80. For the above score, a higher score indicates better QoL.</description>
          <population>The analysis population was the FAS.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="384"/>
                <count group_id="O2" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.400" lower_limit="-0.624" upper_limit="1.424"/>
                    <measurement group_id="O2" value="0.274" lower_limit="-0.709" upper_limit="1.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The model includes treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline FACT-An Ans, baseline Hb, as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.845</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>0.126</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.135</ci_lower_limit>
            <ci_upper_limit>1.387</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL to the Average Value of Weeks 12 to 28 in Total FACT-An Score</title>
        <description>Baseline FACT-An Total Score was defined on Day 1. Total Fact-An score is composed of FACT-G and Ans scales. FACT-G contains 27 items that cover four dimensions of well-being: physical (PWB) - 7 items, functional (FWB) - 7 items, social/family (SWB) - 7 items, and emotional (EWB) - 6 items. The AnS scale contains 13 fatigue specific items (the Fatigue Score) plus 7 items related to anemia. The total score is obtained by summation of the scores from PWB, SWB, EWB, FWB and AnS. The FACT-An Total Score scale range is 0-188. A higher score indicates better QoL.</description>
        <time_frame>Baseline and weeks 12 to 28</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL to the Average Value of Weeks 12 to 28 in Total FACT-An Score</title>
          <description>Baseline FACT-An Total Score was defined on Day 1. Total Fact-An score is composed of FACT-G and Ans scales. FACT-G contains 27 items that cover four dimensions of well-being: physical (PWB) - 7 items, functional (FWB) - 7 items, social/family (SWB) - 7 items, and emotional (EWB) - 6 items. The AnS scale contains 13 fatigue specific items (the Fatigue Score) plus 7 items related to anemia. The total score is obtained by summation of the scores from PWB, SWB, EWB, FWB and AnS. The FACT-An Total Score scale range is 0-188. A higher score indicates better QoL.</description>
          <population>The analysis population was the FAS.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.501" lower_limit="-2.581" upper_limit="1.580"/>
                    <measurement group_id="O2" value="-0.373" lower_limit="-2.367" upper_limit="1.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The model includes treatment, visit, visit by treatment interaction, Previous ESA Treatment, region and history of CV disease as fixed class factors and baseline FACT-An Ans, baseline Hb, as continuous covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.922</p_value>
            <p_value_desc>p-value for superiority test based on 2-sided significance level</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>-0.128</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.703</ci_lower_limit>
            <ci_upper_limit>2.447</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL to the Average of Weeks 12 to 28 in Euroqol Questionnaire-5 Dimensions 5 Levels (EQ-5D 5L) Visual Analogue Scale (VAS) Score</title>
        <description>Baseline assessment was defined as the value on Day 1. The EuroQol Questionnaire -5 Dimensions -5 Levels (EQ-5D-5L) is a self-reported questionnaire, used as a measure of respondents' Health Related Quality of Life (HRQoL) and utility values. The EQ-5D consists of the descriptive system and the visual analogue scale (VAS). The EQ-5D descriptive system comprises 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, extreme problems. The VAS records the respondent's self rated health status on a graduated (0-100) scale, where the endpoints are labeled 'Best imaginable health state' and 'Worst imaginable health state' with higher scores for higher HRQoL.</description>
        <time_frame>Baseline and weeks 12 to 28</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL to the Average of Weeks 12 to 28 in Euroqol Questionnaire-5 Dimensions 5 Levels (EQ-5D 5L) Visual Analogue Scale (VAS) Score</title>
          <description>Baseline assessment was defined as the value on Day 1. The EuroQol Questionnaire -5 Dimensions -5 Levels (EQ-5D-5L) is a self-reported questionnaire, used as a measure of respondents' Health Related Quality of Life (HRQoL) and utility values. The EQ-5D consists of the descriptive system and the visual analogue scale (VAS). The EQ-5D descriptive system comprises 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, extreme problems. The VAS records the respondent's self rated health status on a graduated (0-100) scale, where the endpoints are labeled 'Best imaginable health state' and 'Worst imaginable health state' with higher scores for higher HRQoL.</description>
          <population>The analysis population was the FAS.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="401"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.041" spread="14.910"/>
                    <measurement group_id="O2" value="2.735" spread="14.477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Improvements Measured by Patients' Global Impression of Change (PGIC)</title>
        <description>The PGIC is a patient-rated instrument that measures change in participant's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), when compared to the start of treatment. The percentage of participants presented includes very much improved, much improved and minimally improved.</description>
        <time_frame>Baseline and weeks 8, 12, 28, 36, 52, 76, 104</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvements Measured by Patients' Global Impression of Change (PGIC)</title>
          <description>The PGIC is a patient-rated instrument that measures change in participant's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), when compared to the start of treatment. The percentage of participants presented includes very much improved, much improved and minimally improved.</description>
          <population>The analysis population was the FAS.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6"/>
                    <measurement group_id="O2" value="49.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.5"/>
                    <measurement group_id="O2" value="49.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3"/>
                    <measurement group_id="O2" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4"/>
                    <measurement group_id="O2" value="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2"/>
                    <measurement group_id="O2" value="51.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.6"/>
                    <measurement group_id="O2" value="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL in Serum Hepcidin</title>
        <description>Baseline assessment was assessment from Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.</description>
        <time_frame>Baseline and weeks 4, 12, 20, 36, 52, 104, and End of Study (EOS - up to 108 weeks)</time_frame>
        <population>The analysis population was the FAS, with participants who had available data at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL in Serum Hepcidin</title>
          <description>Baseline assessment was assessment from Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.</description>
          <population>The analysis population was the FAS, with participants who had available data at baseline.</population>
          <units>µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="387"/>
                    <count group_id="O2" value="400"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.265" spread="42.393"/>
                    <measurement group_id="O2" value="-4.265" spread="33.518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="375"/>
                    <count group_id="O2" value="391"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.298" spread="41.335"/>
                    <measurement group_id="O2" value="-6.741" spread="38.507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="361"/>
                    <count group_id="O2" value="382"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.149" spread="43.152"/>
                    <measurement group_id="O2" value="-11.818" spread="41.596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="332"/>
                    <count group_id="O2" value="366"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.405" spread="43.033"/>
                    <measurement group_id="O2" value="-14.530" spread="43.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="310"/>
                    <count group_id="O2" value="357"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.709" spread="42.342"/>
                    <measurement group_id="O2" value="-17.522" spread="47.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="242"/>
                    <count group_id="O2" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.101" spread="48.611"/>
                    <measurement group_id="O2" value="-18.735" spread="51.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="280"/>
                    <count group_id="O2" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.192" spread="52.169"/>
                    <measurement group_id="O2" value="-17.664" spread="51.688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL in Serum Ferritin</title>
        <description>Baseline assessment was assessment from Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.</description>
        <time_frame>Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 104, and EOS (up to 108 weeks)</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL in Serum Ferritin</title>
          <description>Baseline assessment was assessment from Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.</description>
          <population>The analysis population was the FAS.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="408"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-214.64" spread="824.96"/>
                    <measurement group_id="O2" value="-141.78" spread="456.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="394"/>
                    <count group_id="O2" value="405"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-245.37" spread="668.51"/>
                    <measurement group_id="O2" value="-160.75" spread="607.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="389"/>
                    <count group_id="O2" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-269.76" spread="761.24"/>
                    <measurement group_id="O2" value="-179.47" spread="586.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="379"/>
                    <count group_id="O2" value="396"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-337.94" spread="645.73"/>
                    <measurement group_id="O2" value="-246.89" spread="727.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="363"/>
                    <count group_id="O2" value="392"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-427.46" spread="699.95"/>
                    <measurement group_id="O2" value="-265.21" spread="816.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="343"/>
                    <count group_id="O2" value="379"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-507.34" spread="726.61"/>
                    <measurement group_id="O2" value="-269.26" spread="855.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="328"/>
                    <count group_id="O2" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-545.14" spread="668.02"/>
                    <measurement group_id="O2" value="-323.30" spread="986.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="318"/>
                    <count group_id="O2" value="365"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-615.19" spread="677.97"/>
                    <measurement group_id="O2" value="-347.58" spread="1058.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="304"/>
                    <count group_id="O2" value="359"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-622.55" spread="675.22"/>
                    <measurement group_id="O2" value="-394.40" spread="837.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="349"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-604.47" spread="773.19"/>
                    <measurement group_id="O2" value="-456.16" spread="1039.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="283"/>
                    <count group_id="O2" value="339"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-646.76" spread="838.76"/>
                    <measurement group_id="O2" value="-447.70" spread="967.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="333"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-629.31" spread="1060.24"/>
                    <measurement group_id="O2" value="-454.44" spread="1193.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 92</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="258"/>
                    <count group_id="O2" value="326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-749.58" spread="828.32"/>
                    <measurement group_id="O2" value="-371.64" spread="1157.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="250"/>
                    <count group_id="O2" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-746.86" spread="796.74"/>
                    <measurement group_id="O2" value="-364.78" spread="1802.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="308"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-753.82" spread="791.12"/>
                    <measurement group_id="O2" value="-348.70" spread="1292.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-554.53" spread="910.01"/>
                    <measurement group_id="O2" value="-166.94" spread="2035.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL in Transferrin Saturation (TSAT)</title>
        <description>Baseline assessment was assessment from Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.</description>
        <time_frame>Baseline and weeks 4, 8, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, 100, 104 and EOS (up to 108 weeks)</time_frame>
        <population>The analysis population was the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL in Transferrin Saturation (TSAT)</title>
          <description>Baseline assessment was assessment from Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.</description>
          <population>The analysis population was the FAS.</population>
          <units>Percentage of saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="412"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="392"/>
                    <count group_id="O2" value="402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.151" spread="16.147"/>
                    <measurement group_id="O2" value="-2.331" spread="13.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="383"/>
                    <count group_id="O2" value="399"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.681" spread="17.062"/>
                    <measurement group_id="O2" value="-3.128" spread="14.461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="381"/>
                    <count group_id="O2" value="397"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.643" spread="17.551"/>
                    <measurement group_id="O2" value="-3.189" spread="13.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="363"/>
                    <count group_id="O2" value="387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.782" spread="16.634"/>
                    <measurement group_id="O2" value="-4.398" spread="14.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="356"/>
                    <count group_id="O2" value="385"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.463" spread="17.798"/>
                    <measurement group_id="O2" value="-3.829" spread="15.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="336"/>
                    <count group_id="O2" value="372"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.351" spread="17.803"/>
                    <measurement group_id="O2" value="-4.022" spread="15.471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="358"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.069" spread="16.349"/>
                    <measurement group_id="O2" value="-5.254" spread="15.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="313"/>
                    <count group_id="O2" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.278" spread="17.244"/>
                    <measurement group_id="O2" value="-5.788" spread="14.666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="295"/>
                    <count group_id="O2" value="348"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.997" spread="16.774"/>
                    <measurement group_id="O2" value="-5.187" spread="16.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.279" spread="17.809"/>
                    <measurement group_id="O2" value="-6.237" spread="15.934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.156" spread="17.682"/>
                    <measurement group_id="O2" value="-6.623" spread="16.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="270"/>
                    <count group_id="O2" value="331"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.867" spread="17.654"/>
                    <measurement group_id="O2" value="-5.378" spread="17.771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 92</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                    <count group_id="O2" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.996" spread="19.850"/>
                    <measurement group_id="O2" value="-6.259" spread="16.605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="308"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.379" spread="17.809"/>
                    <measurement group_id="O2" value="-6.354" spread="17.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.650" spread="17.842"/>
                    <measurement group_id="O2" value="-5.054" spread="17.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="283"/>
                    <count group_id="O2" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.466" spread="16.626"/>
                    <measurement group_id="O2" value="-3.763" spread="17.813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL in Glycated Hemoglobin (HbA1c) Level to Weeks 12, 28, 36, 44, 52, 60, 84, 104 and EOS (up to Week 108)</title>
        <description>Percentage of change from baseline to each study visit were calculated for HbA1c. Baseline assessment was assessment from Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.</description>
        <time_frame>Baseline and weeks 12, 28, 36, 44, 52, 60, 84, 104 and EOS (up to 108 weeks)</time_frame>
        <population>The analysis population was the FAS, with participants who had available data at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL in Glycated Hemoglobin (HbA1c) Level to Weeks 12, 28, 36, 44, 52, 60, 84, 104 and EOS (up to Week 108)</title>
          <description>Percentage of change from baseline to each study visit were calculated for HbA1c. Baseline assessment was assessment from Day 1 visit. If baseline value was missing, the value from screening visit was used. In case of missing data, no imputation rules were applied.</description>
          <population>The analysis population was the FAS, with participants who had available data at baseline.</population>
          <units>percentage of Glycated Hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="385"/>
                    <count group_id="O2" value="401"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0009" spread="0.0071"/>
                    <measurement group_id="O2" value="-0.0005" spread="0.0057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="360"/>
                    <count group_id="O2" value="389"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0004" spread="0.0067"/>
                    <measurement group_id="O2" value="-0.0006" spread="0.0064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="342"/>
                    <count group_id="O2" value="378"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0001" spread="0.0065"/>
                    <measurement group_id="O2" value="-0.0004" spread="0.0067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="327"/>
                    <count group_id="O2" value="370"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0001" spread="0.0069"/>
                    <measurement group_id="O2" value="-0.0006" spread="0.0067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                    <count group_id="O2" value="363"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0001" spread="0.0070"/>
                    <measurement group_id="O2" value="-0.0007" spread="0.0068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="303"/>
                    <count group_id="O2" value="355"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" spread="0.0080"/>
                    <measurement group_id="O2" value="-0.0004" spread="0.0070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="269"/>
                    <count group_id="O2" value="331"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0003" spread="0.0072"/>
                    <measurement group_id="O2" value="0.0001" spread="0.0078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="242"/>
                    <count group_id="O2" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" spread="0.0075"/>
                    <measurement group_id="O2" value="-0.0003" spread="0.0082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="286"/>
                    <count group_id="O2" value="319"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0011" spread="0.0076"/>
                    <measurement group_id="O2" value="0.0001" spread="0.0080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>Safety was assessed by evaluation of the following variables: (TEAEs; frequency, severity, seriousness, and relationship to study drug), Vital signs (systolic and diastolic blood pressure, pulse, respiratory rate and weight), Clinical laboratory variables (hematology, biochemistry including liver enzymes and total bilirubin, and urinalysis), Physical examination, 12-lead electrocardiogram (ECG) and Vascular Access Thrombosis. All AEs collected during the Safety Emergent Period were counted as TEAE. The TEAE was defined as an adverse event (AE) if it was observed after starting administration of the roxadustat or ESA. Any clinically significant abnormalities were reported as an AEs. All reported deaths after the first study drug administration and up to 28 days after the Analysis Date of Last Dose and considering last dosing frequency.</description>
        <time_frame>Baseline up to EOS (Up to week 108)</time_frame>
        <population>The analysis population was the Safety Analysis Set (SAF) which consisted of all randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>ESA (Erythropoiesis-Stimulating Agent)</title>
            <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>Safety was assessed by evaluation of the following variables: (TEAEs; frequency, severity, seriousness, and relationship to study drug), Vital signs (systolic and diastolic blood pressure, pulse, respiratory rate and weight), Clinical laboratory variables (hematology, biochemistry including liver enzymes and total bilirubin, and urinalysis), Physical examination, 12-lead electrocardiogram (ECG) and Vascular Access Thrombosis. All AEs collected during the Safety Emergent Period were counted as TEAE. The TEAE was defined as an adverse event (AE) if it was observed after starting administration of the roxadustat or ESA. Any clinically significant abnormalities were reported as an AEs. All reported deaths after the first study drug administration and up to 28 days after the Analysis Date of Last Dose and considering last dosing frequency.</description>
          <population>The analysis population was the Safety Analysis Set (SAF) which consisted of all randomized participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="414"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359"/>
                    <measurement group_id="O2" value="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-Related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-Related Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-Related TEAE Leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Withdrawal of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-Related TEAE Leading to Withdraw of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE NCI CTC Grades 3 or Higher</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                    <measurement group_id="O2" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death During the Safety Emergent Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug up to End of Study (EOS) (Up to week 108)</time_frame>
      <desc>The Safety Emergent Period was defined as the evaluation period from the Analysis date of first drug intake up to 28 days after the end of treatment taking into account the different dosing frequencies of the study treatments.</desc>
      <group_list>
        <group group_id="E1">
          <title>Roxadustat</title>
          <description>Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.</description>
        </group>
        <group group_id="E2">
          <title>ESA (Erythropoiesis-Stimulating Agent)</title>
          <description>Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from epoetin alfa to darbepoetin alfa or vice versa.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="414"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="414"/>
                <counts group_id="E2" subjects_affected="189" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="414"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypocoagulable state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="414"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="414"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="414"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="414"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cardiac fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="414"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism secondary</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Toxic goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Anal incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Intestinal ulcer perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Ulcerative gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Catheter site inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Device related thrombosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Medical device site phlebitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Vascular stent stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anti-neutrophil cytoplasmic antibody positive vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Renal transplant failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Acute hepatitis B</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Encephalomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Enterobacter bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Fungal oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="414"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastric ulcer helicobacter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastrointestinal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Medical device site joint infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Osteomyelitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pancreatitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Penile abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="414"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="414"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pyonephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Renal cyst infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="414"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Systemic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Urinary tract infection staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="414"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" events="37" subjects_affected="29" subjects_at_risk="414"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Lip injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Post procedural inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Shunt aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Shunt malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Shunt occlusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Shunt stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Shunt thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Skin wound</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Vascular access malfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Vascular access site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Fistula discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Joint contracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Sarcopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Benign lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Benign renal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour pulmonary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Haemangioma of bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Kidney angiomyolipoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of choroid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Penile cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Refractory anaemia with an excess of blasts</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cerebral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Epileptic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Idiopathic partial epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Vertigo CNS origin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Fear of falling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Mental disorder due to a general medical condition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Organic brain syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Renal cyst ruptured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Urethral perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Urinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Eosinophilic pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pleural thickening</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cutaneous vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Neurodermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Rash vesicular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Toxic epidermal necrolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Catheter placement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Therapy cessation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Diabetic vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="414"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="414"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Steal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Subclavian artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Vasculitis necrotising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Venous stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="414"/>
                <counts group_id="E2" subjects_affected="209" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism secondary</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="414"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="51" subjects_affected="33" subjects_at_risk="414"/>
                <counts group_id="E2" events="60" subjects_affected="32" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="414"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="38" subjects_affected="29" subjects_at_risk="414"/>
                <counts group_id="E2" events="34" subjects_affected="27" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="414"/>
                <counts group_id="E2" events="29" subjects_affected="21" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="61" subjects_affected="28" subjects_at_risk="414"/>
                <counts group_id="E2" events="68" subjects_affected="39" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" events="34" subjects_affected="27" subjects_at_risk="414"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="39" subjects_affected="30" subjects_at_risk="414"/>
                <counts group_id="E2" events="64" subjects_affected="51" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="414"/>
                <counts group_id="E2" events="48" subjects_affected="33" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="41" subjects_affected="36" subjects_at_risk="414"/>
                <counts group_id="E2" events="39" subjects_affected="29" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="101" subjects_affected="66" subjects_at_risk="414"/>
                <counts group_id="E2" events="116" subjects_affected="75" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="40" subjects_affected="30" subjects_at_risk="414"/>
                <counts group_id="E2" events="40" subjects_affected="26" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Overall 838 were randomized to receive treatment. Two participants randomized to the pooled ESA treatment group were excluded due to GCP violations and their data was excluded. Total of 836 were considered randomized.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure</name_or_title>
      <organization>Astellas Pharma Europe B.V.</organization>
      <phone>800-888-7704 ext 5473</phone>
      <email>astellas.resultsdisclosure@astellas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

